

Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023

GBD 2023 Chronic Kidney Disease Collaborators*



Summary

Background Chronic kidney disease (CKD) is common and ranks among the leading causes of mortality and morbidity. This analysis aimed to present global CKD estimates using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 to inform evidence-based policies for CKD identification and treatment.

Methods This analysis focused on adults aged 20 years and older over the period 1990 to 2023, from 204 countries and territories. Data sources used were published literature, vital registration systems, kidney failure treatment registries, and household surveys. Estimates of CKD burden, including deaths, incidence, prevalence, and disability-adjusted life-years (DALYs), were produced using a Cause of Death Ensemble model and a Bayesian meta-regression analytical tool. A comparative risk assessment approach estimated the proportion of cardiovascular deaths attributable to impaired kidney function and estimated risk factors for CKD.

Findings Globally, in 2023, 788 million (95% uncertainty interval 743–843) people aged 20 years and older were estimated to have CKD, up from 378 million (354–407) in 1990. The global age-standardised prevalence of CKD in adults was 14·2% (13·4–15·2), a relative rise of 3·5% (2·7–4·1) from 1990. The region with the highest age-standardised prevalence was north Africa and the Middle East (18·0%; 16·9–19·4). Most people had stage 1–3 CKD, with a combined prevalence of 13·9% (13·1–15·0). In 2023, CKD was the ninth leading cause of death globally, accounting for 1·48 million (1·30–1·65) deaths, and the 12th leading cause of DALYs, with an age-standardised DALY rate of 769·2 (691·8–857·4) per 100 000. Impaired kidney function as a risk factor accounted for 11·5% (8·4–14·5) of cardiovascular deaths. High fasting plasma glucose, body-mass index, and systolic blood pressure were all leading risk factors for CKD DALYs.

Interpretation CKD is a major global health issue, with rising prevalence and increasing importance as a cause of death and as a risk factor for cardiovascular death. A better understating of aetiology, appropriate screening, and implementation programmes are needed to translate advances in CKD treatment into improved patient outcomes.

Funding Gates Foundation, Wellcome, US National Kidney Foundation, and US National Institute of Diabetes and Digestive and Kidney Diseases.

Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction

Chronic kidney disease (CKD), defined either by reduction in estimated glomerular filtration rate (eGFR) or by increased urinary excretion of albumin (or protein), is an important cause of mortality and morbidity globally. Since it is more common in older age, the burden of CKD has increased as the global population ages. The last report from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) on CKD documented a global age-standardised prevalence of CKD of 9·1% (697 million) in 2017, with a higher prevalence and attributable mortality compared to 1990.^{1,2} Updating the global and country-specific estimates of CKD prevalence and risks, with a focus on adults, is important to develop priorities and plans for global health-care initiatives.

The burden associated with CKD extends beyond its most severe form: kidney failure requiring kidney replacement therapy (KRT). A separate GBD report has described the global rise of KRT from 1·59 million in 1990 to 4·59 million in 2023.³ The population affected by CKD is orders of magnitude higher than that of KRT, since the majority of people with CKD experience mortality due to cardiovascular disease, acute kidney injury, and infectious causes including COVID-19^{4,5} before reaching kidney failure. Estimates of the prevalence of CKD depend on the methodology of ascertainment and case definition, as well as region-specific risk factors, but a recent meta-analysis estimated the prevalence of CKD at 13% of adults, with disparities related to age, sex, and socioeconomic status.⁶ Thus, the growing literature on

Lancet 2025; 406: 2461–82

Published Online
November 7, 2025
[https://doi.org/10.1016/S0140-6736\(25\)01853-7](https://doi.org/10.1016/S0140-6736(25)01853-7)

See [Comment](#) page 2401

*Collaborators listed at the end of the Article

Correspondence to:
Professor Patrick B Mark, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow G12 8TA, UK
patrick.mark@glasgow.ac.uk

or
Dr Liane Ong, Institute for Health Metrics and Evaluation (IHME), University of Washington, Seattle, WA 98195, USA
ongl@uw.edu

or
Professor Josef Coresh, Optimal Aging Institute, New York University Grossman School of Medicine, New York, NY 10016-6402, USA
josef.coresh@nyulangone.org

Research in context

Evidence before this study

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has generated publicly available estimates of chronic kidney disease deaths, prevalence, years of life lost, years lived with disability, and disability-adjusted life-years across age, sex, and location since 1990. GBD produces estimates of CKD with each new cycle, but there has not been a comprehensive description and analysis of data, methods, and estimates since GBD 2017. Although several systematic reviews and meta-analyses have been done by other research groups, these analyses have not been as granular demographically and they have focused exclusively on prevalence or deaths. In this study, we present estimates of morbidity, mortality, and the burden of chronic kidney disease by severity. We conducted systematic reviews in PubMed from Jan 1, 1990, to Sep 13, 2022 (appendix 1 section 3.1), carrying out opportunistic searches of renal registries and incorporating data shared by country collaborators. To estimate the burden of cardiovascular disease due to kidney dysfunction, we acquired data on the risk relationship from a systematic review done from Jan 1, 1990, to April 25, 2023, and relative risk data from the Chronic Kidney Disease Prognosis Consortium (appendix 1 section 4.1).

Added value of this study

This study updates and expands on previously published estimates from GBD. We report epidemiological patterns from

1990 to 2023 and describe CKD patterns for adults by stages—a feature that was not included in the previous analysis and is not otherwise publicly available. We also explicitly quantify the proportion of the cardiovascular disease burden attributable to kidney dysfunction and chronic kidney disease burden attributable to selected risk factors. This information is essential to policy makers, health-care professionals, health researchers, and individuals with chronic kidney disease to understand the scale, magnitude, and trajectory of this disease and to guide resource allocation.

Implications of all the available evidence

Chronic kidney disease is a major health condition that both serves as a risk factor for diseases with high morbidity and mortality and is an important cause of disease burden in its own right. Despite its prominent role among non-communicable diseases, it does not engender the same type of attention as other leading causes of health loss from policy makers. This study serves to underscore and quantify the growing impact of chronic kidney disease across age, year, sex, and location that can be used to understand future research needs and areas for intervention as well as societal costs.

See Online for appendix 1

CKD prevalence indicates an even higher burden than previously appreciated.

GBD provides a systematic approach to quantifying not only health loss attributable to disease but also the prevalence of its risk factors. The principal primary cause of CKD globally is diabetes.¹ The rising prevalence of obesity and diabetes,^{7,8} in addition to the ageing of the global population, is likely to lead to a rising burden of CKD.⁹ Additionally, the understanding of specific causes of CKD and populations at risk have evolved. Risk variants in the *APOL1* gene are now established to be major contributors to the excess risk of CKD in people of Black ethnicity, both in North America and west Africa.¹⁰ CKD of unknown aetiology (CKDu) is a major emergent public health concern in many countries in central America and south Asia.¹¹ Thus, while diabetes and hypertension continue to be leading risk factors for CKD,¹ the multifactorial nature of CKD is increasingly being recognised, as is the observation that CKD itself aggravates a range of other health problems, including hypertension.

A detailed estimation of the global prevalence of CKD is important for planning both current and future needs for diagnosis, care, and the corresponding workforce to meet a growing CKD burden. Fortunately, several effective interventions targeting the renin–angiotensin–aldosterone system (including angiotensin-converting enzyme

inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists [MRAs], SGLT2 inhibitors, and GLP-1 receptor agonists), can slow kidney disease progression and reduce the consequent risk of heart attacks, strokes, and heart failure.² GBD, with its broad collection of data sources and statistical modelling approaches, can deliver the most comprehensive estimates of CKD burden placed in the context of other causes of death and disability.¹ We aimed to summarise findings from GBD 2023 on CKD epidemiology in 204 countries and territories, expressed in terms of prevalence, mortality, and disability-adjusted life-years (DALYs) in people aged 20 years and older, as well as the proportion of cardiovascular disease mortality that can be attributed to kidney dysfunction and the contribution of metabolic, behavioural, and environmental risk factors to CKD DALYs. This paper was produced as part of the GBD Collaborator Network and in accordance with the GBD Protocol.¹²

Methods

Overview

This study used de-identified data and was approved by the University of Washington Institutional Review Board (study #9060). To allow comparison of estimates made in populations with different age structures, we report some of the results as age-standardised estimates for adults aged 20 years and older (ie, extrapolated to a

hypothetical population with a standardised age structure). We focused on adults aged 20 years and older since data in children are sparse and the epidemiology of CKD is different in childhood. The standard population was calculated with the non-weighted mean of the age-specific population proportional distributions for all national locations with 2019 populations greater than 5 million from GBD 2021.

This study complies with the GATHER recommendations (appendix 1 table S1).¹³

Mortality

We used 21845 sources since 1980 to estimate deaths for which CKD was the underlying cause (appendix 1 section 2.1). Diagnostic (International Classification of Diseases) codes directly mapped to CKD (appendix 1 table S2) and garbage codes¹⁴ for which CKD could have been the underlying cause of death were eligible for inclusion in the CKD model. Most garbage codes redistributed to CKD were originally coded to hypertension, unspecified anaemia, or heart failure. In 2020, 33% of CKD deaths were defined as garbage codes; this fraction was similar in 2015 (33%) and lower than in 2010 (42%). General methods for processing and standardising mortality data in GBD 2023 are described elsewhere.¹²

We used the Cause of Death Ensemble model (CODEm)¹² to estimate CKD mortality. CODEm uses out-of-sample predictive validity testing to create ensembles of mixed-effects or spatiotemporal Gaussian regression models of mortality rates or cause fractions with varying combinations of predictive covariates. Covariates were assessed on the basis of established relationships with development or management of CKD, with nine covariates included (appendix 1 section 2.3). CODEm results for all causes are scaled to be consistent with all-cause mortality estimates by location, year, age, and sex, the details of which can be found elsewhere.¹²

Non-fatal estimation

We defined prevalent CKD as loss of kidney function, as indicated by eGFR and urinary albumin-to-creatinine ratio (ACR). GBD considers six categories of CKD as defined by level of eGFR (equivalent to Kidney Disease Improving Global Outcomes [KDIGO] G-stages) and ACR (equivalent to KDIGO A-stages) or receipt of kidney replacement therapy. The categories of CKD in GBD are CKD stage 1–2 (KDIGO stage G1–2 with A2–3), stage 3 (KDIGO stage G3), stage 4 (KDIGO stage G4), and stage 5 (KDIGO stage G5), end-stage kidney disease (ESKD) on maintenance dialysis, and kidney transplantation. Due to the nature of epidemiological studies used to estimate CKD prevalence and incidence, the GBD definition of CKD requires only one measurement of eGFR and ACR and therefore deviates from the KDIGO 2024 Clinical Practice Guidelines duration requirement of abnormalities for more than 3 months. The GBD case definitions by CKD category with

corresponding KDIGO categories are presented in appendix 1 (section 3.2.1).

For GBD 2023, we conducted an updated systematic review^{1,15} of the available literature for population-representative studies reporting prevalence or incidence of each CKD stage based on eGFR and ACR values (appendix 1 section 3.1). We considered the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 equation¹⁶ as the reference equation for estimating GFR in adults aged 18 years and older and also included data estimating GFR using the newer CKD-EPI¹⁷ formulas without adjustment. Data from studies using the older Modification of Diet in Renal Disease or Cockcroft–Gault formulas for estimating GFR were included after applying adjustment factors generated by the meta-regression–Bayesian, regularised, trimmed (MR-BRT)¹⁸ tool. Similarly, CKD stage 1–2 data using alternative ACR thresholds (17 mg/g, 20 mg/g, or 25 mg/g) to define elevated urinary ACR were also adjusted to 30 mg/g before modelling (appendix 1 section 3.2.2). Prevalence and incidence data of dialysis and transplantation were largely obtained from national registries for ESKD. There were 2230 data sources in 133 of the 204 countries and territories included in GBD used in the CKD non-fatal estimation process (appendix 1 section 3.1).

We used a hierarchical Bayesian meta-regression modelling tool, DisMod-MR 2.1,¹⁰ to estimate the prevalence of each CKD category separately from 1990 to 2023. DisMod-MR 2.1 applies differential equations to produce a consistent set of estimates based on data or priors for several epidemiological parameters, including prevalence, incidence, remission rate, and excess mortality rate. We also ran a DisMod-MR 2.1 model for CKD stages 3–5 combined. After modelling, we scaled age-sex-year-location-specific prevalence estimates of CKD stages 3, 4, and 5 to sum to the corresponding prevalence of stages 3–5 combined. More details on CKD non-fatal modelling, including covariates, are provided in appendix 1 (section 3.3).

Disability-adjusted life-years

The methods for calculating DALYs have been described elsewhere;¹⁹ in brief, DALYs were the sum of years of life lost (the product of number of deaths and standard life expectancy at each age of death)¹² and years lived with disability (the product of the prevalence of each sequela before death and its corresponding disability weight).¹⁹ For each CKD category, we calculated the proportion of the burden due to five aetiologies: type 1 diabetes, type 2 diabetes, glomerulonephritis, hypertension, and a residual category of other and unspecified causes (appendix 1 section 3.4.1). These aetiology proportions, along with proportions by anaemia severity and proportions by heart failure severity, were applied to prevalence estimates of CKD categories to estimate CKD sequela (appendix 1 sections 3.4.2–3.4.3).

	Prevalence			Deaths		
	Count (thousands), 2023	Age-standardised prevalence (%), 2023	Percentage change in age-standardised prevalence between 1990 and 2023 (%)	Count (thousands), 2023	Age-standardised rate per 100 000, 2023	Percentage change in age-standardised rates between 1990 and 2023 (%)
Global	788 000 (743 000 to 843 000)	14.2% (13.4 to 15.2)	3.5% (2.7 to 4.1)	1480 (1300 to 1650)	26.5 (23.1 to 29.5)	6.1% (-7.6 to 25.5)
Low SDI	111 000 (103 000 to 120 000)	15.2% (14.4 to 16.2)	-3.2% (-3.8 to -2.5)	200 (154 to 243)	35.4 (27.3 to 43.0)	-5.2% (-27.5 to 45.6)
Low-middle SDI	106 000 (99 000 to 114 000)	16.1% (15.2 to 17.3)	-6.5% (-7.1 to -5.8)	185 (146 to 223)	33.8 (26.7 to 40.8)	2.9% (-22.0 to 37.6)
Middle SDI	96 800 (90 600 to 104 000)	16.3% (15.3 to 17.6)	4.3% (3.7 to 5.0)	207 (171 to 240)	39.7 (32.4 to 46.0)	-4.5% (-24.5 to 24.0)
High-middle SDI	185 000 (175 000 to 197 000)	15.1% (14.3 to 16.2)	3.0% (2.0 to 3.9)	282 (251 to 310)	23.0 (20.5 to 25.3)	-23.8% (-36.0 to -7.8)
High SDI	283 000 (267 000 to 303 000)	12.2% (11.5 to 13.1)	4.4% (3.4 to 5.3)	594 (508 to 654)	20.7 (17.9 to 22.6)	14.3% (1.0 to 26.4)
Central Europe, eastern Europe, and central Asia	48 100 (45 100 to 51 200)	13.0% (12.2 to 13.8)	1.4% (0.8 to 2.1)	49.2 (45.7 to 52.7)	12.0 (11.1 to 12.8)	16.9% (6.3 to 28.0)
Central Asia	9240 (8620 to 9860)	16.0% (15.0 to 17.0)	4.0% (2.6 to 5.4)	10.6 (9.77 to 11.6)	20.8 (18.9 to 22.5)	27.1% (11.3 to 44.8)
Armenia	444 (411 to 474)	15.8% (14.7 to 16.8)	3.2% (-0.5 to 6.8)	0.336 (0.303 to 0.375)	10.6 (9.5 to 11.8)	17.6% (-2.6 to 42.0)
Azerbaijan	1110 (1040 to 1190)	15.7% (14.7 to 16.7)	1.8% (0.0 to 3.8)	0.999 (0.774 to 1.25)	15.6 (11.9 to 19.6)	-8.9% (-34.3 to 35.9)
Georgia	535 (504 to 567)	16.3% (15.3 to 17.3)	4.0% (1.4 to 6.8)	0.597 (0.521 to 0.695)	16.2 (14.2 to 18.8)	101.6% (53.3 to 167.0)
Kazakhstan	2060 (1930 to 2190)	16.2% (15.2 to 17.2)	2.9% (-0.1 to 5.5)	2.75 (2.47 to 3.03)	23.6 (21.0 to 26.0)	109.0% (85.2 to 134.4)
Kyrgyzstan	588 (548 to 632)	16.0% (15.1 to 17.0)	2.8% (0.9 to 4.9)	0.479 (0.427 to 0.531)	15.8 (14.1 to 17.4)	-14.0% (-29.6 to 2.9)
Mongolia	279 (261 to 300)	15.9% (14.9 to 16.9)	0.5% (-1.4 to 2.5)	0.291 (0.236 to 0.359)	20.1 (15.6 to 25.0)	-24.7% (-44.0 to 7.1)
Tajikistan	691 (640 to 748)	14.8% (13.9 to 15.8)	-1.0% (-2.6 to 0.6)	0.606 (0.446 to 0.753)	18.9 (14.2 to 23.9)	17.2% (-18.7 to 76.6)
Turkmenistan	489 (457 to 523)	16.5% (15.4 to 17.6)	2.5% (0.9 to 4.4)	0.689 (0.597 to 0.792)	25.0 (21.8 to 28.7)	37.5% (17.3 to 64.0)
Uzbekistan	3040 (2810 to 3260)	16.2% (15.1 to 17.1)	8.2% (5.9 to 10.6)	3.89 (3.55 to 4.26)	25.1 (22.8 to 27.5)	-6.9% (-20.9 to 9.5)
Central Europe	10 200 (9540 to 10 800)	8.5% (8.0 to 9.0)	-1.2% (-2.0 to -0.4)	21.9 (20 to 23.3)	14.9 (13.7 to 15.8)	-5.5% (-12.4 to 2.9)
Albania	191 (178 to 203)	8.1% (7.6 to 8.7)	-1.5% (-3.4 to 0.1)	0.402 (0.303 to 0.541)	15.2 (11.6 to 20.3)	-31.8% (-45.9 to -4.2)
Bosnia and Herzegovina	277 (260 to 297)	8.5% (7.9 to 9.0)	3.6% (1.6 to 5.6)	0.605 (0.436 to 0.764)	15.4 (11.3 to 19.5)	-15.9% (-42.0 to 15.7)
Bulgaria	663 (619 to 707)	8.5% (8.0 to 9.0)	3.9% (2.1 to 5.9)	1.97 (1.76 to 2.19)	21.1 (18.9 to 23.6)	118.3% (91.0 to 147.5)
Croatia	373 (350 to 399)	8.4% (7.9 to 9.0)	1.4% (-0.4 to 3.2)	1.22 (1.09 to 1.33)	20.1 (18.0 to 22.0)	52.5% (36.4 to 74.1)
Czechia	909 (848 to 969)	8.0% (7.5 to 8.6)	-0.3% (-2.2 to 1.3)	1.64 (1.47 to 1.83)	11.4 (10.2 to 12.6)	-10.8% (-21.0 to 1.0)
Hungary	831 (777 to 882)	8.1% (7.7 to 8.6)	0.2% (-1.6 to 2.2)	2.61 (2.36 to 2.85)	19.8 (17.9 to 21.4)	117.8% (101.0 to 135.5)
Montenegro	52.5 (49.2 to 56.3)	8.7% (8.2 to 9.3)	4.5% (2.5 to 6.4)	0.165 (0.125 to 0.213)	24.5 (18.6 to 31.8)	5.9% (-23.7 to 55.3)
North Macedonia	176 (164 to 187)	9.8% (9.1 to 10.4)	1.8% (0.1 to 3.7)	0.378 (0.272 to 0.477)	19.0 (13.8 to 24.0)	-2.8% (-42.9 to 52.1)
Poland	3550 (3320 to 3790)	8.9% (8.4 to 9.5)	-5.4% (-6.1 to -4.8)	5.54 (4.91 to 6.12)	11.2 (9.9 to 12.3)	-42.7% (-49.9 to -35.4)

(Table continues on next page)

	Prevalence			Deaths		
	Count (thousands), 2023	Age-standardised prevalence (%), 2023	Percentage change in age-standardised prevalence between 1990 and 2023 (%)	Count (thousands), 2023	Age-standardised rate per 100 000, 2023	Percentage change in age-standardised rates between 1990 and 2023 (%)
(Continued from previous page)						
Romania	1730 (1640 to 1820)	8.5% (8.1 to 8.9)	-1.2% (-4.2 to 2.3)	3.43 (3.14 to 3.74)	14.2 (13.0 to 15.4)	3.2% (-5.4 to 13.3)
Serbia	634 (596 to 676)	7.4% (7.0 to 7.9)	3.5% (1.1 to 6.9)	2.53 (1.82 to 3.17)	26.6 (19.9 to 33.3)	3.0% (-24.6 to 43.2)
Slovakia	428 (398 to 457)	8.1% (7.6 to 8.6)	-0.4% (-1.9 to 1.5)	0.714 (0.61 to 0.854)	11.8 (10.1 to 14.0)	-33.1% (-46.8 to -15.8)
Slovenia	190 (178 to 203)	8.1% (7.6 to 8.6)	0.2% (-1.7 to 2.0)	0.356 (0.307 to 0.402)	10.5 (9.1 to 11.8)	-3.2% (-15.7 to 11.2)
Eastern Europe	28 700 (26 900 to 30 600)	14.6% (13.7 to 15.6)	0.1% (-0.5 to 0.7)	16.7 (15.2 to 18.4)	7.5 (6.8 to 8.3)	22.2% (5.7 to 40.7)
Belarus	1380 (1290 to 1470)	15.5% (14.5 to 16.5)	2.5% (0.6 to 4.5)	0.492 (0.435 to 0.559)	4.9 (4.3 to 5.6)	14.7% (-5.3 to 38.2)
Estonia	235 (222 to 250)	16.4% (15.3 to 17.5)	2.2% (0.4 to 4.1)	0.773 (0.677 to 0.864)	37.5 (32.9 to 41.7)	101.6% (74.1 to 134.9)
Latvia	331 (309 to 351)	16.1% (15.2 to 17.2)	4.4% (2.6 to 6.5)	0.46 (0.412 to 0.509)	16.9 (15.3 to 18.8)	110.5% (78.2 to 146.3)
Lithuania	489 (458 to 519)	16.2% (15.1 to 17.3)	3.8% (2.0 to 5.7)	0.403 (0.365 to 0.446)	10.4 (9.5 to 11.5)	55.6% (35.0 to 77.6)
Moldova	638 (601 to 677)	18.4% (17.3 to 19.6)	6.4% (3.1 to 9.4)	0.207 (0.185 to 0.232)	5.3 (4.8 to 5.9)	4.9% (-9.7 to 22.8)
Russia	19 300 (18 100 to 20 700)	14.2% (13.3 to 15.2)	-0.3% (-0.8 to 0.3)	12.8 (11.7 to 14.2)	8.3 (7.5 to 9.2)	10.0% (-4.9 to 26.5)
Ukraine	6330 (5900 to 6730)	15.2% (14.2 to 16.3)	1.0% (-0.8 to 2.9)	1.52 (1.35 to 1.7)	3.5 (3.1 to 3.9)	48.0% (17.3 to 76.8)
High income	130 000 (123 000 to 138 000)	10.8% (10.2 to 11.5)	0.6% (0.0 to 1.2)	400 (330 to 448)	23.2 (19.6 to 25.8)	49.4% (33.0 to 67.4)
Australasia	2820 (2640 to 3020)	8.9% (8.3 to 9.5)	-1.3% (-4.2 to 1.9)	6.72 (5.57 to 7.45)	15.6 (13.1 to 17.2)	14.0% (1.5 to 28.4)
Australia	2380 (2220 to 2550)	8.8% (8.3 to 9.5)	-1.6% (-5.2 to 2.3)	5.56 (4.58 to 6.19)	14.9 (12.4 to 16.5)	10.2% (-1.8 to 24.5)
New Zealand	444 (414 to 473)	9.2% (8.5 to 9.8)	0.4% (-1.2 to 2.1)	1.16 (1.01 to 1.29)	19.5 (17.0 to 21.6)	32.8% (18.0 to 51.8)
High-income Asia Pacific	35 300 (33 500 to 37 200)	14.2% (13.4 to 15.1)	-5.4% (-6.3 to -4.6)	67.6 (51 to 79.2)	15.4 (12.1 to 17.8)	-33.2% (-45.7 to -21.5)
Brunei	45.1 (41.9 to 48.6)	15.6% (14.7 to 16.6)	0.5% (-1.5 to 2.4)	0.0965 (0.0762 to 0.118)	46.4 (36.3 to 57.6)	-28.1% (-46.5 to 11.4)
Japan	28 600 (27 000 to 30 300)	15.6% (14.6 to 16.6)	0.4% (-0.2 to 1.0)	56 (42.1 to 65.8)	14.9 (11.7 to 17.3)	-32.8% (-43.7 to -20.9)
Singapore	868 (821 to 914)	16.3% (15.5 to 17.1)	-1.9% (-9.8 to 2.9)	1 (0.856 to 1.11)	17.2 (14.7 to 19.1)	-22.5% (-31.4 to -13.0)
South Korea	5780 (5530 to 6050)	10.5% (10.0 to 11.0)	-18.2% (-22.2 to -14.8)	10.5 (6.1 to 13.7)	16.7 (9.8 to 21.9)	-38.3% (-74.6 to -0.8)
High-income North America	42 100 (39 400 to 44 900)	11.5% (10.8 to 12.3)	3.5% (2.5 to 4.8)	156 (132 to 175)	34.9 (29.7 to 38.8)	177.5% (143.3 to 221.1)
Canada	3780 (3600 to 3960)	9.6% (9.2 to 10.1)	-6.9% (-12.3 to -2.1)	9.67 (8.21 to 10.6)	17.5 (15.0 to 19.1)	73.3% (57.9 to 90.6)
Greenland	4.47 (4.18 to 4.84)	10.9% (10.2 to 11.7)	2.4% (0.4 to 4.5)	0.00842 (0.00501 to 0.0118)	30.4 (17.4 to 43.3)	3.1% (-36.3 to 72.0)
USA	38 300 (35 800 to 40 900)	11.7% (11.0 to 12.6)	5.0% (4.0 to 6.2)	147 (124 to 164)	37.2 (31.5 to 41.4)	189.1% (152.4 to 235.9)
Southern Latin America	6420 (5980 to 6950)	11.8% (10.9 to 12.8)	5.0% (3.1 to 6.8)	25.7 (22.6 to 28.4)	40.3 (35.7 to 44.4)	-9.4% (-18.5 to 0.0)
Argentina	4160 (3860 to 4520)	11.6% (10.7 to 12.6)	6.5% (4.4 to 8.8)	19.2 (16.8 to 21.6)	46.2 (40.5 to 51.9)	-13.6% (-25.7 to -1.7)

(Table continues on next page)

	Prevalence			Deaths		
	Count (thousands), 2023	Age-standardised prevalence (%), 2023	Percentage change in age-standardised prevalence between 1990 and 2023 (%)	Count (thousands), 2023	Age-standardised rate per 100 000, 2023	Percentage change in age-standardised rates between 1990 and 2023 (%)
(Continued from previous page)						
Chile	1880 (1740 to 2030)	12.0% (11.2 to 13.0)	2.1% (-1.1 to 6.7)	5.3 (4.6 to 5.77)	29.5 (25.8 to 32.0)	19.1% (7.4 to 33.1)
Uruguay	379 (354 to 408)	12.6% (11.7 to 13.6)	2.6% (0.1 to 5.2)	1.21 (1.05 to 1.37)	29.1 (25.5 to 32.9)	11.7% (-3.0 to 28.2)
Western Europe	43 700 (41 300 to 46 300)	8.5% (8.0 to 9.1)	-3.4% (-4.1 to -2.6)	144 (117 to 161)	17.6 (14.6 to 19.6)	35.7% (22.1 to 49.9)
Andorra	8.79 (8.25 to 9.4)	9.3% (8.8 to 10.0)	0.2% (-1.7 to 2.0)	0.0216 (0.0159 to 0.0286)	14.2 (10.7 to 18.4)	-14.8% (-39.3 to 33.2)
Austria	977 (921 to 1040)	9.6% (9.0 to 10.2)	3.3% (1.2 to 5.3)	3.96 (3.34 to 4.44)	26.7 (22.6 to 29.9)	163.7% (139.0 to 187.9)
Belgium	1180 (1110 to 1260)	9.4% (8.8 to 10.0)	7.4% (4.7 to 10.7)	3 (2.47 to 3.44)	15.2 (12.6 to 17.3)	-3.1% (-15.8 to 10.7)
Cyprus	116 (108 to 124)	9.8% (9.3 to 10.6)	0.7% (-1.2 to 2.7)	0.42 (0.315 to 0.548)	36.2 (27.5 to 46.9)	-13.1% (-41.2 to 41.7)
Denmark	625 (582 to 668)	9.6% (8.9 to 10.3)	3.0% (0.7 to 5.3)	1.99 (1.69 to 2.25)	21.6 (18.3 to 24.4)	181.8% (143.8 to 222.5)
Finland	683 (641 to 726)	10.1% (9.5 to 10.8)	-4.0% (-6.0 to -2.0)	0.869 (0.706 to 0.995)	8.3 (6.8 to 9.5)	61.1% (42.7 to 80.6)
France	5420 (5100 to 5800)	7.2% (6.7 to 7.8)	3.5% (0.1 to 7.0)	15.6 (13 to 18)	12.4 (10.4 to 14.3)	16.4% (0.6 to 33.0)
Germany	8850 (8450 to 9290)	8.4% (7.9 to 8.9)	-1.5% (-4.5 to 2.1)	42.4 (34.2 to 47.8)	24.2 (19.8 to 27.1)	67.2% (45.9 to 90.1)
Greece	1290 (1210 to 1370)	9.6% (9.0 to 10.2)	0.7% (-1.6 to 2.8)	7.26 (6.33 to 8.06)	34.6 (30.4 to 38.3)	0.3% (-10.8 to 13.6)
Iceland	28.1 (26.2 to 30.1)	8.1% (7.5 to 8.7)	0.8% (-1.8 to 3.5)	0.0443 (0.0363 to 0.0511)	10.3 (8.5 to 11.8)	70.7% (46.1 to 100.6)
Ireland	538 (513 to 568)	11.2% (10.6 to 11.9)	-1.4% (-4.9 to 2.7)	0.652 (0.536 to 0.76)	11.2 (9.2 to 13.0)	-8.3% (-21.4 to 6.3)
Israel	737 (692 to 785)	9.8% (9.2 to 10.5)	0.1% (-1.7 to 2.0)	2.91 (2.45 to 3.34)	31.0 (26.4 to 35.4)	-11.1% (-21.1 to 0.1)
Italy	6120 (5760 to 6560)	8.2% (7.7 to 8.8)	-3.9% (-4.5 to -3.2)	19.3 (15.2 to 22.2)	14.8 (11.9 to 17.0)	11.1% (-4.3 to 26.5)
Luxembourg	50.7 (48 to 53.6)	8.4% (8.0 to 8.9)	-2.4% (-5.8 to 1.3)	0.158 (0.135 to 0.179)	21.0 (18.0 to 23.8)	30.3% (12.4 to 52.8)
Malta	55 (51.6 to 58.5)	9.4% (8.9 to 10.1)	-3.0% (-5.0 to -1.4)	0.148 (0.125 to 0.172)	21.0 (17.8 to 24.3)	9.9% (-5.8 to 28.2)
Monaco	4.83 (4.51 to 5.18)	9.3% (8.7 to 10.0)	0.6% (-1.5 to 2.6)	0.0164 (0.0113 to 0.0234)	20.7 (14.3 to 29.6)	57.9% (0.6 to 169.6)
Netherlands	1650 (1540 to 1770)	9.0% (8.4 to 9.7)	-3.6% (-10.3 to 1.4)	4.46 (3.69 to 5.04)	16.3 (13.6 to 18.4)	57.4% (38.5 to 80.0)
Norway	555 (523 to 592)	10.0% (9.4 to 10.8)	9.2% (8.1 to 10.2)	0.869 (0.704 to 0.998)	11.1 (9.0 to 12.7)	97.1% (66.9 to 130.3)
Portugal	946 (890 to 1020)	7.7% (7.1 to 8.3)	-1.2% (-3.5 to 0.8)	4.73 (3.85 to 5.34)	21.9 (18.1 to 24.6)	14.5% (-1.8 to 30.9)
San Marino	3.83 (3.59 to 4.11)	9.1% (8.5 to 9.8)	-0.5% (-2.2 to 1.6)	0.00744 (0.00528 to 0.0102)	11.3 (8.0 to 15.3)	-16.7% (-43.6 to 36.8)
Spain	4860 (4500 to 5200)	8.6% (8.0 to 9.3)	0.6% (-2.6 to 3.1)	16.8 (13.5 to 19.2)	17.9 (14.6 to 20.5)	-12.7% (-23.2 to -0.6)
Sweden	1440 (1360 to 1520)	11.8% (11.1 to 12.6)	-4.7% (-6.3 to -2.8)	2.82 (2.31 to 3.13)	15.4 (12.8 to 17.1)	151.7% (116.9 to 187.0)
Switzerland	1170 (1100 to 1250)	11.7% (11.1 to 12.5)	4.8% (1.5 to 8.1)	3.13 (2.49 to 3.59)	19.7 (15.7 to 22.5)	73.0% (51.7 to 98.2)
UK	6330 (5910 to 6790)	8.4% (7.8 to 9.0)	-17.6% (-18.3 to -16.9)	12 (10.2 to 13.3)	11.3 (9.7 to 12.5)	68.4% (50.7 to 83.9)

(Table continues on next page)

	Prevalence			Deaths		
	Count (thousands), 2023	Age-standardised prevalence (%), 2023	Percentage change in age-standardised prevalence between 1990 and 2023 (%)	Count (thousands), 2023	Age-standardised rate per 100 000, 2023	Percentage change in age-standardised rates between 1990 and 2023 (%)
(Continued from previous page)						
Latin America and Caribbean	63 600 (59 600 to 67 600)	15.4% (14.4 to 16.4)	1.2% (0.7 to 1.6)	183 (170 to 193)	45.1 (41.6 to 47.6)	30.4% (19.3 to 42.6)
Andean Latin America	4020 (3750 to 4340)	9.5% (8.9 to 10.3)	5.7% (4.1 to 7.1)	17.2 (15.3 to 19.4)	43.6 (38.6 to 49.1)	9.4% (-8.8 to 36.9)
Bolivia	706 (659 to 764)	10.4% (9.8 to 11.2)	1.1% (-0.7 to 3.1)	5.16 (3.98 to 6.61)	92.1 (70.9 to 117.8)	37.7% (0.0 to 121.2)
Ecuador	1150 (1080 to 1250)	10.0% (9.4 to 10.9)	4.6% (2.4 to 7.0)	5.77 (5.31 to 6.13)	52.7 (48.5 to 56.0)	22.8% (13.9 to 32.6)
Peru	2160 (2000 to 2340)	9.1% (8.4 to 9.8)	7.7% (5.0 to 9.8)	6.29 (5.12 to 7.79)	27.7 (22.6 to 34.4)	-17.3% (-34.7 to 10.1)
Caribbean	6080 (5710 to 6460)	17.7% (16.6 to 18.8)	4.9% (3.9 to 6.2)	17.3 (15.6 to 19)	49.0 (44.1 to 53.9)	65.3% (44.0 to 84.9)
Antigua and Barbuda	12.9 (12 to 13.7)	18.0% (16.8 to 19.1)	5.6% (3.8 to 7.4)	0.0503 (0.0445 to 0.0567)	71.1 (62.8 to 80.0)	46.4% (24.7 to 73.0)
The Bahamas	50.8 (47.4 to 54.3)	17.8% (16.6 to 19.0)	5.3% (3.5 to 7.4)	0.179 (0.154 to 0.206)	70.3 (60.5 to 80.5)	86.2% (57.1 to 126.0)
Barbados	51 (47.6 to 54.5)	17.2% (16.1 to 18.3)	5.3% (3.3 to 6.9)	0.17 (0.147 to 0.198)	51.0 (44.3 to 59.2)	54.3% (28.8 to 81.6)
Belize	39 (36.5 to 41.8)	17.8% (16.7 to 18.9)	4.0% (2.2 to 5.9)	0.147 (0.129 to 0.165)	79.8 (69.9 to 89.7)	88.1% (56.5 to 119.6)
Bermuda	11.4 (10.6 to 12.1)	15.8% (14.8 to 16.9)	-0.5% (-2.4 to 1.3)	0.0253 (0.0221 to 0.0288)	28.6 (25.0 to 32.4)	23.9% (7.3 to 46.1)
Cuba	1720 (1610 to 1830)	15.7% (14.7 to 16.7)	-1.1% (-2.9 to 0.7)	3.52 (3.13 to 3.97)	27.4 (24.4 to 30.8)	119.5% (95.4 to 147.5)
Dominica	10.5 (9.77 to 11.2)	18.1% (16.9 to 19.3)	6.3% (4.5 to 8.1)	0.036 (0.0259 to 0.0477)	55.8 (40.3 to 73.7)	46.1% (-0.8 to 114.6)
Dominican Republic	1170 (1090 to 1250)	17.4% (16.2 to 18.6)	4.0% (2.0 to 6.0)	3.65 (2.89 to 4.57)	59.8 (47.5 to 75.0)	81.6% (12.4 to 180.4)
Grenada	17.6 (16.5 to 18.7)	18.9% (17.7 to 20.1)	6.8% (5.0 to 8.4)	0.0718 (0.0618 to 0.0804)	73.9 (64.0 to 82.6)	37.4% (18.7 to 64.5)
Guyana	89.3 (83.4 to 95.5)	18.4% (17.3 to 19.6)	4.7% (3.0 to 6.6)	0.476 (0.413 to 0.55)	106.3 (92.0 to 122.9)	136.0% (95.5 to 188.9)
Haiti	1300 (1210 to 1390)	22.1% (20.7 to 23.6)	9.5% (6.4 to 13.8)	3.08 (2.08 to 4.81)	65.9 (44.4 to 102.9)	41.1% (0.6 to 137.0)
Jamaica	346 (323 to 371)	17.0% (15.9 to 18.2)	4.4% (2.4 to 6.4)	1.06 (0.921 to 1.22)	51.0 (44.2 to 58.6)	35.3% (15.3 to 58.7)
Puerto Rico	714 (669 to 761)	17.5% (16.4 to 18.7)	3.8% (1.8 to 5.7)	2.84 (2.52 to 3.13)	51.0 (45.8 to 56.0)	9.9% (-3.2 to 25.5)
Saint Kitts and Nevis	5.9 (5.5 to 6.3)	16.1% (15.0 to 17.1)	3.4% (1.2 to 5.7)	0.0289 (0.0255 to 0.0327)	84.0 (74.0 to 95.0)	34.8% (13.6 to 62.0)
Saint Lucia	26.4 (24.5 to 28.1)	17.7% (16.4 to 18.8)	2.5% (0.7 to 4.6)	0.0934 (0.0821 to 0.106)	60.9 (53.5 to 69.2)	17.8% (0.5 to 40.6)
Saint Vincent and the Grenadines	16.8 (15.7 to 17.9)	17.8% (16.6 to 18.9)	6.2% (4.2 to 8.0)	0.0584 (0.0517 to 0.0666)	58.0 (51.3 to 66.2)	57.6% (33.1 to 89.3)
Suriname	71.1 (66.1 to 76.1)	17.2% (16.0 to 18.5)	1.8% (0.0 to 3.6)	0.235 (0.193 to 0.288)	58.8 (48.2 to 72.5)	29.0% (-7.9 to 99.1)
Trinidad and Tobago	207 (193 to 222)	17.9% (16.7 to 19.1)	6.2% (4.5 to 8.3)	0.947 (0.803 to 1.1)	88.9 (76.3 to 101.9)	91.7% (61.4 to 122.7)
Virgin Islands	16.8 (15.7 to 17.8)	17.3% (16.3 to 18.4)	3.2% (1.7 to 4.6)	0.055 (0.0472 to 0.0627)	47.0 (40.7 to 53.5)	20.1% (0.2 to 43.6)
Central Latin America	30 800 (28 900 to 32 800)	18.0% (16.8 to 19.1)	2.0% (1.4 to 2.5)	102 (95.6 to 108)	62.0 (57.7 to 65.7)	44.6% (32.1 to 61.1)
Colombia	6010 (5630 to 6410)	16.2% (15.2 to 17.2)	-1.8% (-3.6 to -0.1)	7.7 (6.94 to 8.27)	20.5 (18.5 to 22.0)	-32.0% (-37.1 to -27.6)

(Table continues on next page)

(Continued from previous page)

	Prevalence			Deaths		
	Count (thousands), 2023	Age-standardised prevalence (%), 2023	Percentage change in age-standardised prevalence between 1990 and 2023 (%)	Count (thousands), 2023	Age-standardised rate per 100 000, 2023	Percentage change in age-standardised rates between 1990 and 2023 (%)
Costa Rica	718 (670 to 768)	18.7% (17.5 to 20.0)	-1.0% (-4.4 to 2.6)	2.07 (1.84 to 2.31)	55.4 (49.0 to 61.7)	113.8% (94.4 to 139.5)
El Salvador	615 (585 to 651)	15.5% (14.7 to 16.4)	1.3% (-1.9 to 4.3)	4.97 (3.31 to 6.55)	129.7 (86.5 to 170.7)	141.0% (9.4 to 366.6)
Guatemala	1490 (1390 to 1590)	18.4% (17.2 to 19.7)	9.8% (8.1 to 11.6)	5.98 (5.4 to 6.71)	88.4 (79.1 to 98.4)	67.1% (43.1 to 94.3)
Honduras	860 (799 to 925)	17.0% (15.8 to 18.2)	0.5% (-1.5 to 2.5)	2.03 (1.49 to 2.88)	52.9 (38.7 to 75.1)	33.9% (-5.9 to 138.1)
Mexico	16 600 (15 500 to 17 600)	18.9% (17.6 to 20.1)	3.4% (2.8 to 3.9)	59.4 (55.3 to 63.2)	69.9 (65.0 to 74.4)	42.1% (28.7 to 61.9)
Nicaragua	654 (611 to 702)	18.4% (17.2 to 19.6)	6.8% (2.9 to 10.5)	3.25 (2.24 to 3.98)	107.3 (77.9 to 129.2)	52.2% (-17.1 to 144.5)
Panama	595 (566 to 622)	20.9% (19.9 to 21.9)	9.5% (5.3 to 14.1)	1.42 (1.28 to 1.56)	48.9 (44.2 to 53.4)	116.0% (88.8 to 148.6)
Venezuela	3280 (3060 to 3510)	17.3% (16.2 to 18.5)	-2.2% (-3.7 to -0.6)	15.4 (12.7 to 18.1)	88.8 (73.1 to 105.1)	172.6% (121.6 to 232.9)
Tropical Latin America	22 700 (21 200 to 24 200)	13.8% (12.9 to 14.7)	-1.2% (-1.9 to -0.6)	46.7 (41.6 to 50.9)	28.1 (25.0 to 30.6)	4.7% (-4.1 to 13.7)
Brazil	22 200 (20 700 to 23 700)	13.8% (12.9 to 14.7)	-1.3% (-2.0 to -0.6)	45.1 (40.2 to 49.1)	27.7 (24.6 to 30.1)	3.5% (-5.9 to 11.8)
Paraguay	525 (493 to 565)	14.0% (13.1 to 15.0)	1.6% (-0.3 to 3.6)	1.6 (1.12 to 1.97)	49.7 (34.7 to 61.5)	69.9% (10.6 to 142.6)
North Africa and Middle East	64 100 (59 800 to 69 300)	18.0% (16.9 to 19.4)	6.2% (5.5 to 7.1)	163 (128 to 198)	64.9 (50.7 to 79.0)	-14.7% (-41.4 to 25.8)
North Africa and Middle East	64 100 (59 800 to 69 300)	18.0% (16.9 to 19.4)	6.2% (5.5 to 7.1)	163 (128 to 198)	64.9 (50.7 to 79.0)	-14.7% (-41.4 to 25.8)
Afghanistan	2190 (2010 to 2420)	18.0% (16.8 to 19.5)	7.7% (5.4 to 10.2)	3.24 (2.27 to 4.23)	63.3 (44.4 to 81.2)	-17.5% (-44.3 to 21.2)
Algeria	4570 (4240 to 4940)	17.1% (16.0 to 18.5)	4.2% (2.1 to 6.3)	11.6 (7.95 to 15.5)	53.7 (36.8 to 72.7)	0.7% (-38.2 to 53.7)
Bahrain	166 (153 to 182)	17.3% (16.2 to 18.6)	0.4% (-1.4 to 2.5)	0.23 (0.158 to 0.317)	60.3 (40.3 to 82.1)	-15.8% (-45.2 to 27.3)
Egypt	9430 (8720 to 10 200)	17.7% (16.5 to 19.0)	10.1% (8.1 to 12.9)	46.9 (35.2 to 59.6)	146.2 (107.3 to 185.4)	7.5% (-34.9 to 68.2)
Iran	12 700 (12 000 to 13 700)	22.7% (21.3 to 24.2)	17.2% (15.7 to 18.9)	13.1 (9.16 to 17)	31.9 (22.5 to 41.6)	-24.1% (-52.8 to 25.0)
Iraq	3800 (3490 to 4140)	18.1% (16.9 to 19.5)	2.6% (0.5 to 4.6)	7.62 (5.43 to 10.3)	64.8 (46.7 to 89.6)	-7.7% (-39.5 to 47.8)
Jordan	1140 (1060 to 1250)	16.5% (15.4 to 17.7)	-3.3% (-5.2 to -1.6)	2.83 (2.26 to 3.46)	64.9 (51.1 to 79.6)	-1.8% (-30.0 to 50.3)
Kuwait	477 (436 to 525)	16.5% (15.4 to 17.9)	-3.6% (-6.0 to -1.4)	0.385 (0.329 to 0.445)	38.7 (32.1 to 45.5)	-41.9% (-51.0 to -31.3)
Lebanon	662 (616 to 717)	17.1% (16.1 to 18.5)	1.5% (-0.5 to 3.6)	1.72 (1.27 to 2.18)	43.1 (31.7 to 53.8)	10.2% (-24.6 to 86.3)
Libya	825 (759 to 899)	18.8% (17.5 to 20.4)	10.8% (8.2 to 13.1)	2.06 (1.17 to 3.07)	69.2 (39.6 to 103.6)	34.8% (-33.8 to 120.2)
Morocco	3730 (3450 to 4050)	15.3% (14.1 to 16.4)	1.0% (-1.2 to 3.3)	16.1 (12 to 21.5)	85.2 (64.0 to 115.5)	2.3% (-32.3 to 46.9)
Oman	463 (421 to 516)	17.3% (16.2 to 18.8)	8.1% (6.1 to 10.2)	0.604 (0.427 to 0.793)	64.8 (46.6 to 84.8)	23.8% (-24.0 to 95.2)
Palestine	404 (373 to 443)	16.9% (15.8 to 18.2)	0.3% (-1.5 to 2.1)	0.806 (0.616 to 1.01)	56.8 (42.6 to 72.0)	-12.5% (-39.5 to 21.2)
Qatar	299 (268 to 334)	16.7% (15.6 to 17.9)	-2.6% (-5.0 to -0.4)	0.164 (0.128 to 0.208)	51.6 (38.1 to 64.7)	-39.7% (-60.5 to -14.9)

(Table continues on next page)

	Prevalence			Deaths		
	Count (thousands), 2023	Age-standardised prevalence (%), 2023	Percentage change in age-standardised prevalence between 1990 and 2023 (%)	Count (thousands), 2023	Age-standardised rate per 100 000, 2023	Percentage change in age-standardised rates between 1990 and 2023 (%)
(Continued from previous page)						
Saudi Arabia	2960 (2710 to 3260)	17.2% (16.2 to 18.6)	-1.0% (-2.8 to 1.0)	7.28 (5.41 to 9.41)	113.7 (84.0 to 147.1)	12.7% (-28.0 to 61.4)
Sudan	3170 (2940 to 3460)	17.5% (16.4 to 19.0)	3.6% (1.2 to 5.8)	8.88 (5.85 to 12)	75.5 (49.9 to 102.0)	-10.2% (-45.3 to 30.4)
Syria	1750 (1630 to 1900)	17.2% (16.2 to 18.6)	1.5% (-0.5 to 3.2)	5.78 (3.68 to 7.95)	94.1 (59.4 to 129.4)	21.9% (-20.9 to 81.7)
Tunisia	1390 (1300 to 1500)	16.5% (15.4 to 17.8)	1.3% (-0.9 to 3.8)	2.93 (2.14 to 3.82)	38.8 (28.7 to 49.9)	-26.9% (-50.3 to 11.4)
Türkiye	10 500 (9770 to 11 300)	17.0% (15.8 to 18.3)	0.7% (-1.6 to 3.1)	26.8 (21.4 to 34.1)	47.5 (37.7 to 60.1)	-31.6% (-55.2 to 5.6)
United Arab Emirates	1120 (1010 to 1250)	16.8% (15.7 to 18.2)	-2.3% (-4.5 to 0.2)	0.872 (0.568 to 1.15)	72.9 (47.3 to 100.0)	13.6% (-41.4 to 104.5)
Yemen	2250 (2060 to 2500)	16.1% (15.0 to 17.3)	2.1% (0.1 to 4.1)	3.22 (2.18 to 4.99)	44.9 (31.0 to 68.1)	-22.5% (-50.0 to 15.2)
South Asia	170 000 (160 000 to 183 000)	15.8% (14.9 to 16.9)	-11.2% (-12.0 to -10.4)	173 (134 to 218)	18.8 (14.5 to 23.5)	-21.9% (-43.0 to 11.6)
South Asia	170 000 (160 000 to 183 000)	15.8% (14.9 to 16.9)	-11.2% (-12.0 to -10.4)	173 (134 to 218)	18.8 (14.5 to 23.5)	-21.9% (-43.0 to 11.6)
Bangladesh	14 000 (13 100 to 15 000)	15.1% (14.3 to 16.0)	3.8% (1.2 to 7.2)	20.9 (16.4 to 26.8)	27.1 (21.2 to 34.6)	-16.9% (-40.1 to 26.1)
Bhutan	70.7 (66.2 to 76.3)	15.4% (14.5 to 16.4)	2.4% (0.7 to 4.1)	0.147 (0.0747 to 0.234)	34.7 (17.7 to 55.2)	-7.7% (-37.7 to 37.9)
India	138 000 (129 000 to 148 000)	16.0% (15.1 to 17.1)	-14.6% (-15.4 to -13.7)	124 (94.8 to 163)	16.8 (12.8 to 21.9)	-26.0% (-48.1 to 5.8)
Nepal	2440 (2270 to 2620)	14.0% (13.1 to 15.0)	-0.7% (-3.8 to 2.7)	3.15 (2.08 to 4.25)	19.9 (13.2 to 26.7)	-9.8% (-42.2 to 31.0)
Pakistan	15 900 (14 800 to 17 100)	15.2% (14.3 to 16.1)	9.3% (7.9 to 10.9)	24.9 (12.8 to 35.3)	28.4 (14.6 to 40.1)	4.9% (-30.9 to 51.9)
Southeast Asia, east Asia, and Oceania	242 000 (228 000 to 259 000)	13.9% (13.0 to 15.0)	7.9% (6.4 to 9.1)	337 (291 to 379)	18.3 (15.8 to 20.8)	-31.7% (-45.1 to -9.5)
East Asia	158 000 (148 000 to 170 000)	12.3% (11.5 to 13.3)	7.1% (5.2 to 8.8)	167 (138 to 193)	11.7 (9.6 to 13.6)	-50.0% (-62.9 to -29.4)
China	152 000 (142 000 to 164 000)	12.3% (11.5 to 13.2)	7.6% (5.5 to 9.3)	153 (124 to 179)	11.0 (9.0 to 13.0)	-52.3% (-65.3 to -31.4)
North Korea	2440 (2280 to 2620)	12.2% (11.4 to 13.1)	-0.5% (-2.4 to 1.6)	4.51 (3.09 to 6.24)	23.6 (16.0 to 32.6)	11.3% (-23.6 to 81.2)
Taiwan*	3440 (3170 to 3660)	14.1% (13.2 to 15.0)	-5.5% (-9.8 to -3.5)	9.9 (8.19 to 11.3)	33.8 (28.3 to 38.3)	-8.1% (-19.9 to 5.5)
Oceania	994 (920 to 1080)	15.4% (14.4 to 16.5)	5.0% (3.7 to 6.3)	1.68 (1.29 to 2.01)	36.1 (27.3 to 44.4)	7.5% (-26.1 to 50.1)
American Samoa	5.18 (4.81 to 5.6)	17.6% (16.4 to 18.9)	7.3% (5.1 to 9.3)	0.0279 (0.0204 to 0.0359)	107.3 (79.0 to 139.0)	43.0% (1.1 to 125.7)
Cook Islands	1.76 (1.65 to 1.9)	16.2% (15.2 to 17.5)	1.3% (-1.2 to 3.8)	0.00443 (0.00328 to 0.00569)	37.6 (28.0 to 48.6)	25.3% (-10.5 to 103.0)
Federated States of Micronesia	8.65 (8.05 to 9.41)	16.1% (15.0 to 17.3)	6.1% (3.6 to 8.1)	0.0392 (0.0309 to 0.0491)	93.5 (73.3 to 118.8)	-3.0% (-37.4 to 41.7)
Fiji	90.1 (83.8 to 97.2)	16.9% (15.8 to 18.2)	5.4% (3.5 to 7.3)	0.371 (0.269 to 0.491)	83.1 (60.4 to 110.6)	62.0% (-3.5 to 143.8)
Guam	19.4 (18.3 to 20.9)	16.2% (15.2 to 17.4)	8.4% (6.4 to 10.3)	0.0594 (0.0531 to 0.0662)	48.1 (42.9 to 53.7)	65.7% (43.3 to 94.6)
Kiribati	9.97 (9.19 to 10.9)	16.6% (15.5 to 17.8)	6.5% (4.8 to 8.4)	0.0215 (0.0147 to 0.0285)	42.6 (28.6 to 57.8)	44.3% (-9.5 to 103.6)
Marshall Islands	3.12 (2.89 to 3.4)	16.1% (15.0 to 17.2)	5.5% (3.4 to 7.5)	0.021 (0.0141 to 0.0289)	148.2 (99.1 to 203.4)	54.5% (3.8 to 135.7)

(Table continues on next page)

	Prevalence			Deaths		
	Count (thousands), 2023	Age-standardised prevalence (%), 2023	Percentage change in age-standardised prevalence between 1990 and 2023 (%)	Count (thousands), 2023	Age-standardised rate per 100 000, 2023	Percentage change in age-standardised rates between 1990 and 2023 (%)
(Continued from previous page)						
Nauru	0.825 (0.76 to 0.904)	16.6% (15.6 to 17.8)	3.4% (1.4 to 5.2)	0.00828 (0.00381 to 0.0126)	239.7 (111.8 to 364.2)	37.5% (-5.8 to 105.1)
Niue	0.223 (0.209 to 0.24)	16.9% (15.7 to 18.1)	5.2% (3.3 to 7.2)	0.00104 (0.000694 to 0.00144)	73.2 (48.7 to 100.5)	43.2% (-14.9 to 120.3)
Northern Mariana Islands	5.14 (4.78 to 5.55)	16.6% (15.6 to 17.9)	8.7% (6.5 to 10.8)	0.0255 (0.0199 to 0.0322)	109.2 (86.0 to 136.0)	38.4% (0.7 to 106.6)
Palau	2.24 (2.1 to 2.43)	16.6% (15.6 to 17.8)	1.6% (-0.1 to 3.7)	0.00867 (0.00626 to 0.0117)	76.7 (54.9 to 104.0)	25.4% (-15.3 to 96.1)
Papua New Guinea	692 (640 to 756)	14.9% (13.9 to 16.0)	6.0% (4.3 to 8.0)	0.692 (0.499 to 0.91)	20.4 (14.0 to 27.0)	-1.8% (-31.4 to 52.3)
Samoa	18.3 (17.1 to 19.7)	16.6% (15.6 to 17.9)	8.2% (6.2 to 10.4)	0.072 (0.0476 to 0.102)	67.3 (44.5 to 95.2)	56.5% (3.6 to 130.5)
Solomon Islands	60 (55.5 to 65.1)	16.2% (15.2 to 17.4)	8.7% (5.9 to 11.6)	0.154 (0.119 to 0.205)	52.7 (39.4 to 68.4)	3.9% (-35.1 to 51.9)
Tokelau	0.182 (0.171 to 0.195)	16.5% (15.5 to 17.8)	6.7% (4.7 to 8.9)	0.000673 (0.000429 to 0.000929)	57.8 (37.1 to 79.9)	34.6% (-16.3 to 111.8)
Tonga	8.94 (8.33 to 9.66)	16.4% (15.3 to 17.7)	6.3% (4.3 to 8.6)	0.0464 (0.0246 to 0.0709)	90.9 (48.4 to 139.6)	74.7% (3.4 to 164.7)
Tuvalu	1.03 (0.961 to 1.11)	17.2% (16.1 to 18.4)	8.5% (6.5 to 10.8)	0.00668 (0.00416 to 0.00938)	134.2 (82.5 to 188.5)	49.3% (-4.5 to 127.2)
Vanuatu	25 (23.1 to 27.2)	16.6% (15.6 to 17.8)	4.5% (2.1 to 6.4)	0.0509 (0.0331 to 0.0827)	39.8 (26.0 to 65.0)	27.7% (-13.3 to 107.5)
Southeast Asia	83 200 (78 300 to 89 800)	17.9% (16.9 to 19.3)	3.8% (2.9 to 4.8)	168 (137 to 201)	38.6 (31.8 to 46.6)	3.2% (-18.0 to 43.8)
Cambodia	1640 (1520 to 1780)	16.7% (15.6 to 18.1)	1.5% (-0.5 to 3.6)	1.79 (1.25 to 2.42)	21.0 (14.4 to 28.4)	-23.2% (-50.1 to 25.7)
Indonesia	33 400 (31 100 to 36 200)	18.4% (17.2 to 19.9)	5.6% (4.7 to 6.5)	54.8 (38.5 to 73.6)	31.7 (21.9 to 43.6)	9.1% (-24.1 to 59.5)
Laos	682 (631 to 744)	17.4% (16.4 to 18.8)	-0.5% (-2.4 to 1.5)	2.2 (1.67 to 2.88)	69.0 (52.7 to 90.6)	16.3% (-21.7 to 103.0)
Malaysia	4580 (4380 to 4810)	20.7% (19.8 to 21.6)	6.5% (2.2 to 10.7)	7.55 (5.6 to 9.32)	40.4 (29.8 to 50.3)	6.2% (-22.5 to 57.2)
Maldives	58.3 (53.2 to 64.4)	18.0% (16.8 to 19.3)	1.6% (-0.7 to 3.5)	0.135 (0.103 to 0.163)	85.5 (65.8 to 104.5)	1.6% (-24.0 to 63.0)
Mauritius	204 (191 to 218)	19.2% (18.0 to 20.5)	5.9% (4.1 to 7.9)	1.28 (1.18 to 1.37)	114.8 (105.8 to 122.7)	-1.8% (-9.0 to 5.5)
Myanmar	6060 (5610 to 6560)	17.9% (16.6 to 19.3)	2.9% (1.0 to 5.3)	14.2 (9.21 to 20.6)	46.3 (29.8 to 68.1)	-12.5% (-40.2 to 48.1)
Philippines	11 500 (10 700 to 12 500)	18.5% (17.3 to 19.9)	2.9% (2.4 to 3.4)	29.5 (24.4 to 35.1)	58.3 (48.0 to 69.5)	16.6% (-9.6 to 59.2)
Seychelles	14.7 (13.7 to 15.9)	19.2% (18.0 to 20.9)	5.3% (3.1 to 7.4)	0.0471 (0.0352 to 0.0616)	62.9 (47.0 to 82.2)	20.2% (-20.1 to 89.1)
Sri Lanka	3050 (2850 to 3290)	17.8% (16.7 to 19.3)	0.7% (-1.4 to 2.8)	7.44 (5.55 to 9.51)	40.1 (30.1 to 50.9)	-5.9% (-33.1 to 42.1)
Thailand	10 700 (10 300 to 11 100)	17.2% (16.6 to 17.9)	-3.1% (-6.9 to 0.8)	29.6 (22.9 to 36.4)	41.2 (32.0 to 50.7)	-1.1% (-29.9 to 49.4)
Timor-Leste	121 (112 to 132)	18.0% (16.7 to 19.4)	5.8% (3.4 to 8.1)	0.266 (0.19 to 0.381)	47.4 (34.3 to 67.8)	-15.5% (-40.8 to 35.3)
Viet Nam	11 200 (10 400 to 12 200)	15.8% (14.7 to 17.1)	3.4% (1.0 to 6.0)	18.7 (11.7 to 26.6)	26.9 (16.5 to 38.3)	-19.6% (-47.0 to 23.2)
Sub-Saharan Africa	69 500 (64 500 to 75 500)	15.6% (14.7 to 16.7)	2.4% (1.9 to 2.9)	177 (136 to 220)	53.0 (40.5 to 65.9)	6.4% (-22.6 to 55.4)
Central sub-Saharan Africa	8700 (8080 to 9490)	17.7% (16.6 to 19.0)	-1.1% (-2.4 to 0.1)	17.8 (12.9 to 23.2)	45.5 (33.2 to 59.4)	10.8% (-21.3 to 66.4)

(Table continues on next page)

	Prevalence			Deaths		
	Count (thousands), 2023	Age-standardised prevalence (%), 2023	Percentage change in age-standardised prevalence between 1990 and 2023 (%)	Count (thousands), 2023	Age-standardised rate per 100 000, 2023	Percentage change in age-standardised rates between 1990 and 2023 (%)
(Continued from previous page)						
Angola	2040 (1880 to 2220)	17.9% (16.7 to 19.2)	1.8% (0.3 to 3.6)	3.41 (2.44 to 4.43)	38.5 (28.1 to 49.4)	-6.1% (-33.3 to 46.8)
Central African Republic	383 (356 to 414)	18.4% (17.3 to 19.6)	1.8% (0.1 to 3.7)	0.624 (0.415 to 0.877)	37.8 (25.6 to 53.8)	3.9% (-27.7 to 59.2)
Congo (Brazzaville)	417 (387 to 455)	18.5% (17.4 to 19.9)	2.4% (0.7 to 4.4)	0.832 (0.531 to 1.17)	51.2 (32.6 to 71.7)	30.0% (-9.8 to 91.0)
DR Congo	5600 (5190 to 6100)	17.5% (16.4 to 18.8)	-2.5% (-4.3 to -0.9)	12.2 (8.54 to 16.3)	47.1 (32.5 to 64.4)	14.1% (-21.5 to 74.1)
Equatorial Guinea	96.8 (89.4 to 106)	18.4% (17.2 to 19.6)	4.1% (2.2 to 6.2)	0.227 (0.138 to 0.316)	61.6 (37.8 to 85.3)	9.6% (-27.6 to 72.6)
Gabon	161 (151 to 172)	18.3% (17.3 to 19.5)	1.7% (-0.1 to 3.9)	0.485 (0.221 to 0.763)	63.2 (28.8 to 99.2)	42.1% (-12.5 to 97.0)
Eastern sub-Saharan Africa	21 800 (20 100 to 24 100)	12.5% (11.6 to 13.6)	4.2% (3.4 to 5.0)	73.4 (57.6 to 91.4)	57.1 (44.8 to 71.1)	2.8% (-24.6 to 58.2)
Burundi	636 (577 to 709)	12.8% (11.9 to 14.0)	3.9% (1.6 to 6.1)	1.53 (1.06 to 2.17)	46.1 (32.3 to 65.5)	6.9% (-26.9 to 80.7)
Comoros	56.3 (52 to 61.3)	13.0% (12.1 to 14.1)	3.3% (1.0 to 5.8)	0.104 (0.0705 to 0.139)	26.2 (17.7 to 35.1)	-10.7% (-40.5 to 31.6)
Djibouti	78.6 (72.1 to 86.4)	12.4% (11.4 to 13.4)	5.3% (3.3 to 7.7)	0.178 (0.127 to 0.236)	40.3 (28.3 to 52.9)	-13.3% (-41.7 to 34.0)
Eritrea	354 (326 to 388)	11.9% (11.0 to 13.0)	2.8% (0.7 to 5.1)	1.05 (0.717 to 1.48)	43.3 (29.7 to 60.6)	-2.7% (-34.3 to 48.9)
Ethiopia	5840 (5400 to 6400)	12.5% (11.6 to 13.5)	8.2% (7.0 to 9.3)	24.7 (19.4 to 32.3)	65.0 (50.4 to 85.6)	9.0% (-23.8 to 96.7)
Kenya	2830 (2610 to 3100)	12.6% (11.7 to 13.6)	3.3% (2.8 to 3.8)	12.4 (8.87 to 16)	73.6 (52.2 to 93.3)	1.9% (-35.2 to 58.5)
Madagascar	1450 (1320 to 1610)	12.5% (11.7 to 13.6)	1.7% (-0.4 to 3.8)	4.48 (3.22 to 6.24)	66.2 (47.8 to 91.6)	-14.2% (-40.9 to 37.1)
Malawi	926 (846 to 1030)	12.4% (11.5 to 13.4)	-3.0% (-5.5 to -0.4)	2.91 (2.19 to 3.65)	55.3 (41.7 to 70.7)	3.8% (-26.3 to 53.6)
Mozambique	1510 (1380 to 1670)	13.0% (12.0 to 14.1)	4.1% (1.7 to 6.4)	2.64 (1.91 to 3.57)	32.4 (24.1 to 43.6)	5.1% (-37.3 to 96.7)
Rwanda	729 (671 to 804)	12.3% (11.5 to 13.4)	-1.0% (-3.3 to 1.3)	2.78 (2 to 3.59)	65.0 (46.9 to 83.1)	-10.6% (-38.8 to 43.4)
Somalia	927 (853 to 1020)	12.3% (11.5 to 13.4)	5.6% (3.1 to 7.9)	2.07 (1.35 to 2.82)	37.3 (24.1 to 50.6)	13.9% (-26.9 to 66.6)
South Sudan	458 (421 to 503)	12.5% (11.6 to 13.6)	3.9% (1.7 to 6.2)	1.97 (1.5 to 2.57)	75.6 (56.1 to 97.4)	0.7% (-29.7 to 57.2)
Uganda	1870 (1710 to 2090)	12.0% (11.0 to 13.0)	-5.4% (-8.2 to -2.8)	7.01 (5.3 to 9.22)	65.6 (48.0 to 87.1)	-4.2% (-33.4 to 46.7)
Tanzania	3250 (2980 to 3600)	12.7% (11.8 to 13.8)	7.7% (5.7 to 10.1)	6.56 (4.61 to 8.39)	34.9 (24.1 to 44.5)	-3.5% (-32.8 to 44.9)
Zambia	900 (814 to 995)	12.9% (11.9 to 14.0)	9.8% (7.3 to 12.0)	2.89 (2.13 to 3.74)	63.9 (46.0 to 81.2)	-0.3% (-33.7 to 49.0)
Southern sub-Saharan Africa	8600 (8050 to 9240)	18.3% (17.2 to 19.5)	4.1% (3.3 to 4.8)	16.3 (12.9 to 19.4)	40.7 (31.8 to 48.6)	31.2% (-10.5 to 85.0)
Botswana	224 (210 to 240)	17.7% (16.6 to 19.0)	2.5% (0.7 to 4.3)	0.249 (0.177 to 0.35)	22.9 (16.3 to 32.1)	26.5% (-22.4 to 110.5)
Eswatini	99.3 (92.8 to 107)	18.2% (17.2 to 19.5)	5.2% (3.0 to 7.0)	0.22 (0.135 to 0.313)	46.6 (28.8 to 66.0)	-21.6% (-54.3 to 25.6)
Lesotho	164 (154 to 177)	17.9% (16.8 to 19.1)	5.7% (3.6 to 7.6)	0.366 (0.27 to 0.494)	46.7 (34.2 to 63.4)	8.6% (-35.3 to 75.9)
Namibia	225 (207 to 243)	17.2% (16.1 to 18.4)	-1.9% (-3.6 to 0.3)	0.312 (0.225 to 0.457)	28.7 (20.5 to 42.4)	-8.2% (-39.8 to 41.3)

(Table continues on next page)

	Prevalence			Deaths		
	Count (thousands), 2023	Age-standardised prevalence (%), 2023	Percentage change in age-standardised prevalence between 1990 and 2023 (%)	Count (thousands), 2023	Age-standardised rate per 100 000, 2023	Percentage change in age-standardised rates between 1990 and 2023 (%)
(Continued from previous page)						
South Africa	6730 (6310 to 7220)	18.4% (17.3 to 19.6)	3.7% (2.8 to 4.6)	13.8 (10.8 to 16.8)	44.5 (34.7 to 54.3)	35.1% (-3.5 to 84.9)
Zimbabwe	1150 (1070 to 1240)	17.9% (16.8 to 19.1)	5.7% (3.4 to 7.9)	1.35 (0.96 to 1.82)	24.4 (17.4 to 32.9)	23.2% (-29.7 to 111.1)
Western sub-Saharan Africa	30 300 (28 300 to 32 900)	17.2% (16.2 to 18.2)	2.3% (1.6 to 3.1)	69.9 (51.4 to 90.8)	54.7 (39.7 to 70.8)	4.1% (-26.5 to 51.9)
Benin	734 (677 to 799)	14.8% (13.9 to 15.9)	1.5% (-0.7 to 3.7)	1.49 (1.06 to 1.92)	40.8 (28.8 to 52.1)	-20.0% (-44.1 to 23.2)
Burkina Faso	1210 (1120 to 1320)	14.4% (13.6 to 15.5)	3.6% (1.7 to 5.6)	3 (2.19 to 3.84)	47.5 (34.1 to 61.9)	-20.2% (-43.0 to 20.5)
Cabo Verde	43.8 (40.7 to 47.4)	14.8% (13.8 to 15.9)	3.2% (1.0 to 5.6)	0.0925 (0.0624 to 0.126)	32.2 (22.0 to 43.4)	26.9% (-20.3 to 119.6)
Cameroon	1980 (1850 to 2160)	17.2% (16.2 to 18.2)	11.2% (8.4 to 13.7)	6.69 (4.25 to 9.3)	86.0 (55.1 to 121.3)	-2.5% (-34.7 to 37.7)
Chad	783 (723 to 861)	14.4% (13.5 to 15.5)	3.1% (1.0 to 5.1)	2.04 (1.48 to 2.8)	54.8 (40.2 to 74.6)	-1.8% (-31.0 to 57.1)
Côte d'Ivoire	1890 (1730 to 2090)	15.4% (14.4 to 16.5)	2.0% (-0.1 to 4.3)	4.25 (2.96 to 5.67)	52.7 (36.2 to 70.3)	12.6% (-25.6 to 66.3)
The Gambia	146 (135 to 159)	15.3% (14.4 to 16.5)	6.6% (4.4 to 9.0)	0.29 (0.204 to 0.377)	40.6 (28.4 to 53.2)	17.8% (-22.8 to 84.2)
Ghana	1810 (1660 to 2010)	12.1% (11.2 to 13.2)	2.0% (-0.2 to 4.7)	7.32 (5.35 to 9.56)	67.6 (48.9 to 88.4)	9.3% (-27.5 to 60.9)
Guinea	760 (705 to 834)	15.0% (14.1 to 16.2)	6.5% (4.6 to 9.0)	1.91 (1.42 to 2.45)	49.5 (37.1 to 65.0)	-16.0% (-40.4 to 36.9)
Guinea-Bissau	116 (107 to 128)	15.5% (14.5 to 16.6)	4.7% (2.3 to 6.9)	0.319 (0.221 to 0.402)	62.6 (43.3 to 78.7)	14.2% (-17.4 to 73.4)
Liberia	351 (324 to 386)	15.5% (14.5 to 16.5)	4.6% (2.5 to 7.0)	1.27 (0.784 to 1.79)	79.7 (49.1 to 113.6)	1.9% (-30.7 to 54.3)
Mali	1160 (1070 to 1270)	14.7% (13.7 to 15.8)	4.7% (2.4 to 7.0)	2.36 (1.73 to 3.09)	41.2 (30.1 to 54.2)	-5.1% (-30.0 to 47.9)
Mauritania	257 (237 to 280)	14.5% (13.6 to 15.6)	0.6% (-1.3 to 2.6)	0.95 (0.615 to 1.25)	69.8 (45.3 to 92.3)	22.2% (-13.7 to 87.6)
Niger	1040 (958 to 1140)	13.9% (13.0 to 14.9)	3.0% (1.2 to 4.9)	2.14 (1.42 to 3.12)	44.9 (30.3 to 64.5)	-10.6% (-36.6 to 49.3)
Nigeria	16 100 (15 000 to 17 400)	20.3% (19.1 to 21.5)	3.9% (3.1 to 4.8)	31 (21.9 to 44.1)	53.5 (37.4 to 76.8)	10.1% (-24.8 to 67.3)
São Tomé and Príncipe	15.6 (14.5 to 17)	16.0% (15.0 to 17.1)	4.3% (2.4 to 6.4)	0.0387 (0.027 to 0.05)	50.7 (35.0 to 65.8)	11.1% (-24.7 to 64.2)
Senegal	975 (894 to 1070)	13.3% (12.3 to 14.3)	-0.3% (-2.6 to 1.9)	2.1 (1.51 to 2.86)	38.6 (27.3 to 53.0)	5.6% (-27.8 to 65.9)
Sierra Leone	478 (443 to 529)	15.0% (14.1 to 16.1)	2.6% (0.4 to 5.0)	1.39 (1.06 to 1.74)	62.2 (47.8 to 78.0)	-1.8% (-32.9 to 46.5)
Togo	506 (469 to 548)	14.7% (13.7 to 15.6)	1.5% (-0.4 to 3.4)	1.24 (0.912 to 1.61)	49.4 (36.0 to 63.5)	1.5% (-28.0 to 46.7)

Data in parentheses are 95% uncertainty intervals. All count data reported are presented to three significant figures, while rates and percentages are presented to one decimal place. GBD super-regions are created by grouping countries based on epidemiological and geographical similarity into 21 regions, with these regions further grouped into seven, mutually exclusive super-regions. The high-income super-region includes Australasia, high-income Asia Pacific, high income North America, Southern Latin America and western Europe (see appendix section 6, table S17 for the full GBD location hierarchy). SDI=Socio-demographic Index. *UN convention recognises Taiwan as a province of China. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.

Table: Prevalence of, and deaths due to, chronic kidney disease in 2023, and percentage change of age-standardised rates by location, 1990 to 2023, for adults aged 20 years and older

Risk-attributable burden

We estimated CKD stage 1–5 not including kidney replacement therapy, termed kidney dysfunction, as a risk factor for cardiovascular disease (including

ischaemic heart disease, stroke, and peripheral vascular disease). We also estimated seven risk factor groups for CKD: high fasting plasma glucose, high body-mass index (BMI), high systolic blood pressure, dietary risks

(diet low in fruits, vegetables, or whole grains, or high in sodium, red meat, processed meat, or sugar-sweetened beverages), low physical activity, non-optimal temperature (low and high, representing acute cold and heat exposures²⁰), and lead exposure in bone.

We estimated the relative risk of each outcome occurring as a function of exposure to the given risk factor by following the burden of proof approach established by Zheng and colleagues.^{18,21} In brief, we conducted systematic reviews of the available literature that estimated cardiovascular or CKD risk relative to risk factor exposure. Literature data on the cardiovascular risk relative to kidney dysfunction exposure were supplemented by relative risk data provided by the Chronic Kidney Disease Prognosis Consortium.⁴ We used the MR-BRT tool to synthesise input data to generate a relative risk curve by relying on an ensemble spline method to capture the potentially non-linear shape of the risk–outcome relationship; integrating over varying exposure ranges in different comparison groups; trimming potentially distorting outliers; and quantifying remaining between-study heterogeneity through random-effects modelling and incorporating this value into uncertainty around the mean relative risk curve.

We used DisMod-MR 2.1 or spatiotemporal Gaussian process regression to estimate exposure distributions for each risk factor by sex, age, year, and location, as established previously.²² We set the theoretical minimum risk exposure level (TMREL) for kidney dysfunction at an ACR of 30 mg/g or lower and eGFR of 60 mL/min per 1.73 m² or higher, given that this population is at the lowest risk for cardiovascular disease events secondary to kidney dysfunction.²³ Details about the TMREL for the remaining risk factors are provided in appendix 1 (section 4). Exposure, relative risk, and TMREL were used to calculate population attributable fractions (PAFs) for each outcome and risk by location, age, sex, and year. PAFs were multiplied by metrics of disease burden—in this case, CKD DALYs or cardiovascular mortality—to estimate the risk-attributable burden.

Uncertainty and presentation of results

At each modelling step described above, 250 samples from each age-sex-location-year-specific parameter distribution were drawn to propagate parameter uncertainty forward through each subsequent analysis step. 95% uncertainty intervals (UIs) for final estimates were calculated by generating 250 random draws from the estimate distribution and taking the 2.5th and 97.5th percentile values across the 250 draws, linearly interpolating between the sixth and seventh, and the 243rd and 244th of ordered draws.

All count data reported are presented to three significant figures, while rates and percentages are presented to one decimal place.

Geographical locations reported

CKD estimates were generated for 204 countries and territories grouped on the basis of epidemiological and geographical similarity into 21 regions, with these regions further grouped into seven mutually exclusive super-regions (see appendix 1 section 6, table S17, for the full GBD location hierarchy). Socio-demographic Index (SDI) is a summary measure of development, calculated as a composite of a country's total fertility rate for women younger than 25 years, educational attainment, and lag-distributed income per capita.²⁴ Locations at the most granular level estimated by GBD were grouped into SDI quintile groups based on their 2023 SDI values (appendix 1 section 6, table S18).

Data and code availability

Metadata for GBD estimates (including the measure, metrics, risk factors, cause, location, age, sex, and year) are publicly available and can be extracted by registered users via the GBD Results tool. Analyses were done with R (version 4.4.1).

For the GBD Results tool see <https://vizhub.healthdata.org/gbd-results/>

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or the writing of the report.

Results

Total CKD prevalence

Globally in 2023, an estimated 788 million (95% UI 743–843) people aged 20 years and older were living with CKD, a marked rise from 378 million (354–407) in 1990 and 627 million (589–671) in 2013 (table; appendix 1 table S13). The countries with the highest number of individuals with CKD in 2023 were China (152 million; 142–164) and India (138 million; 129–148), with the USA, Indonesia, Japan, Brazil, Russia, Mexico, Nigeria, Pakistan, Bangladesh, Iran, the Philippines, Viet Nam, Thailand, and Türkiye all having more than 10 million adults with CKD.

In 2023, the global age-standardised prevalence of CKD was 14.2% (95% UI 13.4–15.2) of adults, up from 13.7% (12.9–14.7) in 1990 and 13.8% (13.0–14.7) in 2013 (table; appendix 1 table S13). The crude prevalence increased from 12.3% (11.5–13.2) in 1990 to 13.3% (12.5–14.2) in 2013 and 14.6% (13.8–15.6) in 2023, an 18.9% (16.7–20.9) rise reflecting the ageing of the world's population, compared to a rise of 3.5% (2.7–4.1) in the age-standardised prevalence (table; appendix 1 tables S13–S14). There was notable variation across geographical regions (figure 1A). In 2023, the GBD super-regions with the highest age-standardised prevalence of CKD were north Africa and the Middle East (18.0%; 16.9–19.4), south Asia (15.8%; 14.9–16.9), sub-Saharan Africa (15.6%; 14.7–16.7), and Latin America and the Caribbean (15.4%; 14.4–16.4). The high-income super-region had the lowest age-standardised prevalence of




Figure 1: Global age-standardised total chronic kidney disease prevalence (A) and death rates per 100 000 (B) in 2023 in people aged 20 years and older

CKD (10·8%; 10·2–11·5; table). The countries with the highest age-standardised prevalence of CKD were Iran, Haiti, Panama, Nigeria, Mauritius, Seychelles, Grenada, Mexico, Libya, and Costa Rica (table, figure 1A).

CKD prevalence by stage and kidney replacement therapy

The majority of people with CKD were reported to have stage 1–3 CKD (figure 2). Overall, the breakdown of the global age-standardised prevalence of CKD not requiring kidney replacement therapy was 9·0% (95% UI 8·3–9·9) for stage 1–2, 4·5% (4·2–4·9) for stage 3, 0·4% (0·3–0·5) for stage 4, and 0·2% (0·1–0·2) for stage 5; the combined prevalence of stage 1–3 CKD was 13·9% (13·1–15·0; appendix 1 table S15). There was notable variation in the prevalence of CKD stages by age, where a predominance of more severe stages was seen in older adults (figure 2, appendix 1 table S15). By contrast, the prevalence of patients treated with dialysis and transplant rose with age and then fell at the oldest ages. The high-income super-region had the highest prevalence of patients receiving

dialysis and transplant despite generally having a prevalence of stages 1–5 that is lower than the global estimate. Although globally the prevalence of people receiving dialysis was considerably greater than those with a kidney transplant, this imbalance was particularly notable in southeast Asia, east Asia, and Oceania; Latin America and the Caribbean; and north Africa and the Middle East. There was an extremely low relative prevalence of both dialysis and transplantation in sub-Saharan Africa (appendix 1 table S15).

Total CKD mortality

In 2023, globally, there were 1·48 million (95% UI 1·30–1·65) deaths for which CKD was the underlying cause in adults aged 20 years and older (table). The global age-standardised death rate due to CKD was 26·5 (23·1–29·5) deaths per 100 000, with marked variation across SDI quintiles and geographical regions (table, figure 1B). There were 35·4 (27·3–43·0) deaths per 100 000 in the lowest SDI quintile compared to 20·7 (17·9–22·6) deaths per 100 000 in the highest SDI quintile.




Figure 2: Chronic kidney disease stage prevalence by age, globally, and by GBD super-region in 2023

GBD super-regions are created by grouping countries based on epidemiological and geographical similarity into 21 regions, with these regions further grouped into seven, mutually exclusive super-regions. The high-income super-region includes Australasia, high-income Asia Pacific, high-income North America, southern Latin America and western Europe (see appendix section 6, table S17, for the full GBD location hierarchy). GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.




Figure 3: Leading causes of global deaths, DALYs, and leading CVD mortality risk factors in 2023, age-standardised for people aged 20 years and older
The listed population attributable fractions do not take into account mediation between risk factors. Therefore, the sum of the population attributable fractions might exceed 100%.
CVD=cardiovascular disease. DALY=disability-adjusted life-year.




Figure 4: Number of chronic kidney disease DALYs attributable to risk factors globally by age in 2023
DALYs might be attributed to more than one risk factor or not be attributed to any risk factor. Therefore, the sum of the attributable DALYs might not be equal to the total chronic kidney disease DALYs. DALY=disability-adjusted life-year.

Between 1990 and 2023, global age-standardised mortality rates due to CKD in adults rose from 24.9 (95% UI 21.0 to 28.8) per 100 000 to 26.5 (23.1 to 29.5) per 100 000, an increase of 6.1% (–7.6 to 25.5; table; appendix 1 figure S19). In 2023, CKD was ranked ninth among causes of death globally, only the rate of deaths due to Alzheimer’s disease and diabetes rose from 1990 to 2023 (appendix 1 figure S19). The ten countries with the highest

age-standardised mortality rates due to CKD were Nauru, Marshall Islands, Egypt, Tuvalu, El Salvador, Mauritius, Saudi Arabia, Northern Mariana Islands, American Samoa, and Nicaragua (table, figure 1B).

DALYs due to CKD
In 2023, globally, CKD resulted in 769.2 (95% UI 691.8–857.4) age-standardised DALYs per 100 000 among adults aged 20 years and older. Globally, CKD was the 12th leading cause of DALYs in 2023 (figure 3). There were regional differences, with CKD accounting for 1408.6 (1127.4–1714.8) DALYs per 100 000 in sub-Saharan Africa, and north Africa and the Middle East (1360.3 [1102.3–1597.0] per 100 000) and Latin America and the Caribbean (1320.8 [1225.2–1426.7] per 100 000) having age-standardised DALY rates attributable to CKD that were more than 70% higher than global rates (appendix 1 table S16).

Attributable fraction of cardiovascular mortality
PAFs for cardiovascular mortality, the leading cause of death globally, rank kidney dysfunction seventh among the environmental and occupational, behavioural, and metabolic risk factors examined. In 2023, 11.5% (95% UI 8.4–14.5) of global deaths due to cardiovascular disease were attributable to kidney dysfunction (figure 3). The proportion of cardiovascular deaths attributable to kidney dysfunction as a risk factor rose steadily with age (appendix 1 figure S20). Globally, kidney dysfunction ranked seventh as a risk factor for deaths due to cardiovascular disease, below systolic blood pressure but above high fasting plasma glucose and high BMI (figure 3).

Risk factors for CKD DALYs

The five leading risk factors contributing to age-standardised DALYs due to CKD by PAF were high fasting plasma glucose (31.9%; 95% UI 19.8–46.9), high systolic blood pressure (24.5%; 11.7–37.4), high BMI (23.5%; 12.6–34.5), diet (17.6%; 9.6–26.7), and non-optimal temperature (4.4%; 3.1–6.1; appendix 1 figure S19C). High BMI was a proportionately smaller risk factor in south Asia (14.1%; 7.0–23.1) and southeast Asia and Oceania (12.7%; 6.4–21.3); the leading risk factors were otherwise similar across GBD super-regions. The number of CKD DALYs attributable to a risk factor rose with each increasing decade in age from 20 to 69 years. The rise with age was strongest for high systolic blood pressure, which overtook BMI at age 70 years, while high fasting plasma glucose remained the highest contributor to CKD DALYs at all ages (figure 4).

Discussion

This updated GBD report highlights the continued rise in CKD prevalence and associated DALYs over the past three decades.¹ In 2023, 788 million people were estimated to have CKD. The global age-adjusted prevalence of CKD was 14.2% among adults aged 20 years and older. The high CKD prevalence aligns with global population growth and ageing. In 2023, CKD was the ninth leading cause of death, the 12th leading cause of DALYs, and the seventh leading cause of cardiovascular mortality, behind high systolic blood pressure and dietary risks and ahead of high blood glucose and high BMI, all of which are also CKD risk factors. These data support the WHO decision “to advance kidney disease as a non-communicable disease of increasing global priority, in addition to cancer, cardiovascular diseases (heart disease and stroke), diabetes and respiratory diseases, as well as mental health, which have been recognized as the major causes of death and disability”.²⁵

The persistently high age-standardised prevalence and mortality attributable to CKD is global but most notable in regions with a high prevalence of diabetes, such as the Middle East and Oceania. Since the last report, our understanding of factors beyond diabetes and hypertension driving the epidemic of CKD has evolved. The high burden of CKD in central America is likely to be related to CKDu,²⁶ a disease of reduced kidney function in the absence of diabetes, glomerulonephritis, or kidney structural abnormality, classically described in agricultural workers in central America. The more rapidly progressive and deadly course of CKDu might account for increasing age-standardised deaths and DALYs due to CKD in these and other tropical or sub-tropical regions. The aetiology of CKDu is still unknown, but excess heat stress (which might include global warming), infections, and toxins have been implicated.¹¹ Climate change, through rising average global temperatures and an increasing frequency of extreme weather events, is likely to cause a rise in CKD

and accelerated decline in kidney function attributed to non-optimal temperature.^{20,27} The high burden of CKD in west Africa is likely to be driven in part by both vascular risk factors and *APOL1* genetic variants, which increase susceptibility to CKD while being a protective factor for endemic infections.¹⁰ Other genetic factors might be revealed with exome sequencing in up to 10% of people who otherwise have an unknown cause of CKD.²⁸ Most studies of CKD do not report the cause of the disease despite it being a criterion in the classification of CKD along with stage determined by GFR and albuminuria categories.²

CKD DALYs are very high around the world. Preventing cardiovascular events and slowing CKD progression are key to reducing the economic and functional consequences of CKD in both high and low SDI regions. Beyond long established, inexpensive treatments (eg, to improve hyperglycaemia and blood pressure control), newly proven therapies including SGLT2 inhibitors, non-steroidal MRAs, and GLP-1 receptor agonists complement the established strategies for renal angiotensin–aldosterone system inhibition to prevent major adverse cardiovascular and kidney events in people with CKD.^{29–31} The most effective protective treatments for CKD are more recently established and have been implemented less uniformly than prevention programmes for communicable diseases (eg, improved sanitation and vaccinations), and non-communicable diseases (eg, cancer screening and cholesterol lowering), which reduced the mortality attributable to the other leading causes of death, resulting in an older population at risk of CKD and contributed to its rising rank as a cause of death.^{2,32}

With increasing age, CKD incidence and prevalence increases markedly.² However, the outcomes associated with CKD change with age, as the risk of kidney failure replacement therapy and the relative risk of mortality decrease at the oldest ages, while attributable risk of mortality increases. As kidney dysfunction becomes a more prominent risk factor for cardiovascular disease with increasing age, implementing risk-reduction strategies, with appropriate consideration of the potential for harm, also becomes more important with advancing age. Beyond CKD associated with ageing and cardiometabolic disease, for specific causes of CKD such as *APOL1* kidney disease and IgA nephropathy, there are additional new disease-specific agents. All of these general and disease-specific therapies are under-prescribed in high-income countries,²⁶ with potentially less use globally, where limitations could be due to the cost to individuals or health-care systems or shortage of testing and programmes to implement therapies. Political conflicts and instability further challenge effective CKD management, including life-sustaining dialysis therapy.

Contributing to suboptimal disease prevention, all treatment strategies for CKD rely on detection of a largely asymptomatic condition. Albuminuria is

reversibly and strongly associated with adverse kidney and cardiovascular outcomes.⁴ Despite strong guideline-based recommendations for widespread testing of albuminuria in people at risk of CKD, uptake has been limited (ie, 35% of individuals with diabetes and only 4% of individuals with hypertension), even in high-income regions.³³ Even where electronic health-care records could support automated detection of CKD, approximately 30% of affected individuals do not have a diagnosis of CKD in their clinical record.³⁴ This report can inform strategies to recognise and diagnose CKD more efficiently and easily, integrate CKD into general medical care, and target education and planning efforts for the clinical workforce needed for effective nephroprotective therapies.

As highlighted in other reports, the approach used by GBD has the strengths of allowing comprehensive reporting of the mortality and morbidity associated with CKD, without omitting regions where data are scarce. GBD continues to update input data and methodology (appendix 1 sections 3.1–3.2) so comparisons should be within a given GBD model, but we did confirm that including all updates in the current model is within 4% of the previously published 2017 CKD prevalence estimate. In contrast to previous reports on CKD, we focused on adults aged 20 years and older to address the public health implications of CKD in the context of the ageing and increasingly multimorbid global population,¹ and also to recognise the need for different sampling methodologies and statistics for quantifying CKD in children, in whom the disease can be severe but uncommon. Our approach is complementary to that of the International Society of Nephrology Global Kidney Health Atlas³⁵: although the data are not validated and might not be reliable, their approach focuses on existing CKD registries and workforce surveys of nephrology providers to provide estimates of the CKD burden, as well as providing estimates of the availability of nephrology diagnostics and treatments by world region.

This report has some limitations. First, we relied on published estimates and modelling. Second, cross-sectional prevalence estimates typically rely on estimates from a single visit without following guidance to confirm CKD at a second visit or with clinical information: this can inflate CKD prevalence estimates as it does for other non-communicable diseases, including diabetes and hypertension. Third, CKD prevalence estimates can vary according to the GFR estimate used. Published studies have not yet updated GFR estimates from the 2009 CKD-EPI GFR estimating equations to the more recent 2021 equations, and qualitative dipstick measures of albuminuria were not included. Although we standardised alternative case definitions to a gold standard, we did not have access to the level of detail and nuance needed to understand the impact of the selected GFR equation on CKD prevalence estimates across world regions. Fourth, populations with heterogeneous features will introduce

additional biases and uncertainty in risk factor attribution. Fifth, data on albuminuria are often missing, so we were unable to account for it in more severe levels of CKD. Sixth, our estimates filled in data for all countries and years, but source data were scarce, particularly in Africa and low SDI regions, for albuminuria (appendix 1 figures S5–S11) and for risk factors in these regions. Robust data collection in these areas would provide more reliable estimates of the true prevalence and impact of CKD in these areas and warrant specific attention. Seventh, data on children and adolescents with CKD (aged <20 years) are not robust and merit their own analysis, so we did not include this age group in this study. Detailed estimates by sex can be tabulated in the GBD Results tool. Eighth, the underlying cause of CKD is rarely known in population-based studies. Ninth, assigning the underlying cause of death involves uncertainty for all causes, including CKD. Finally, comparisons of trends are valid within a given GBD analysis but not between reports that use different standard populations, and major world-events including conflicts and COVID-19 were not analysed.

In summary, the number of people with CKD and the age-standardised death rate due to CKD continues to rise, in contrast to most of the other top ten leading causes of death globally. This is happening despite the growing number of evidence-based therapies to slow progression of CKD, mitigate its associated excess cardiovascular mortality, and postpone the need for expensive kidney replacement therapies. The wide variation in the availability of kidney replacement therapy globally remains an important health concern. Urgent actions are required to address the data gaps on CKD prevalence estimates, underlying causes of CKD (particularly diabetes), and ensure widespread availability of therapies to improve outcomes for people with CKD.

GBD 2023 Global Chronic Kidney Disease Collaborators

Patrick B Mark*, Lauryn K Stafford*, Morgan E Grams*, Hasan Aalruz, Samar Abd ElHafeez, Ahmed Abdelrahman Abdelgalil, Rizwan Suliankatchi Abdulkader, Hansani Madushika Abeywickrama, Olugbenga Olusola Abiodun, Dmitry Abramov, Mohammed Mehdi Abrar, Lucas Guimarães Abreu, Bilyaminu Abubakar, Salahdein Aburuz, Isaac Yeboah Addo, Oyelola A Adegboye, Nurudeen A Adegoke, Temitayo Esther Adeyeoluwa, Qorinah Estiningtyas Sakilah Adnani, Bright Opoku Ahinkorah, Sajjad Ahmad, Khabir Ahmad, Ali Ahmadi, Amir Mahmoud Ahmadzade, Ayman Ahmed, Aram Mahmood Ahmed, Nesredin Ahmed, Shahzaib Ahmed, Syed Anees Ahmed, Marjan Ajami, Mohammadreza Akbari, Oluwasefunmi Akeju, Mohammed Ahmed Akkaif, Salah Al Awaidey, Hanadi Al Hamad, Syed Mahfuz Al Hasan, Yazan Al Taher, Ziyad Al-Aly, Fahmi Y Al-Ashwal, Mohammed Albashtawy, Shereen M Aleidi, Ali M Alfalki, Fadwa Naji Alhalaqi, Khalid A Alhasan, Endale Alemayehu Ali, Rafat Ali, Syed Shujait Ali, Syed Yusuf Ali, Samah W Al-Jabi, Mohammed Z Allouh, Wesam Taher Almagharbeh, Omar Almidani, Khaldoun Aied Alnawafleh, Najim Z Alshahrani, Awaish Altat, Nelson Alvis-Guzman, Yaser Mohammed Al-Worafi, Kareem H Alzoubi, Adel Sharaf Al-Zubairi, Masoud Aman Mohammadi, Hubert Amu, Filippas Anagnostakis, Abhishek Anil, Anayochukwu Edward Anyasodor, Geminn Louis Carace Apostol,

Walter Appati, Sulaimon O Araromi, Aleksandr Y Aravkin, Johan Årnlöv, Jesu Arockiaraj, Bernard Kwadwo Yeboah Asiamah-Asare, Yuni Asri, Ashagre Molla Assaye, Maha Moh'd Wahbi Atout, Khursheed Aurangzeb, Adedapo Wasiu Awotidebe, Sadat Abdulla Aziz, Domenico Azzolino, Muhammad Badar, Mohamad Amin Bakhshali, Shoshana H Ballew, Ovidiu Constantin Baltatu, Maciej Banach, Mainak Bardhan, Hiba Jawdat Barqawi, MD Abu Bashar, Shahid Bashir, Mohammad-Mahdi Bastan, Saurav Basu, Neeraj Bedi, Bekalu Mekonen Belay, Makda Abate Belew, Aminu K Bello, Luis Belo, Amiel Nazer C Bermudez, Akshaya Srikanth Bhagavathula, Sonu Bhaskar, Ajay Nagesh Bhat, Priyadarshini Bhattacharjee, Jasvinder Singh Bhatti, Gurjit Kaur Bhatti, Sibhatu Kassa Biadgilign, Yacong Bo, Trupti Bodhare, Archith Boloor, Hamed Borhany, Michael Brauer, Raffaele Bugiardin, Akeem Olayinka Busari, Yasser Bustanji, Luis Alberto Cámera, Luciana Aparecida Campos, Ismael Campos-Nonato, Juan Jesus Carrero, Márcia Carvalho, Alberico L Catapano, Monica Cattafesta, Muthia Cenderadewi, Edina Cenko, Deepak Chandramohan, Vijay Kumar Chattu, Lam Duc Chau, Anis Ahmad Chaudhary, An-Tian Chen, Haojin Cheng, Nicholas WS Chew, Patrick R Ching, Hou In Chou, Sonali Gajanan Choudhari, Enayet Karim Chowdhury, Dinh-Toi Chu, Sheng-Chia Chung, Alyssa Columbus, Paolo Angelo Cortesi, Karen Courville, Natalia Cruz-Martins, Omid Dadras, Lalit Dandona, Rakhi Dandona, Anh Kim Dang, Saswati Das, Tadesse Asmamaw Dejenie, Vinoth Gnana Chellaiyan Devanbu, Devananda Devegoda, Syed Masudur Rahman Dewan, Mandira Lamichhane Dhimal, Meghnath Dhimal, Daniel Diaz, Huyen Phuc Do, Thao Huynh Phuong Do, Linh Phuong Doan, Mario D'Oria, Robert Kokou Dowou, Ashel Chelsea Dsouza, Bruce B Duncan, Siddhartha Dutta, Cynthia Edeh, Hisham Atan Edinur, Ferry Efendi, Michael Ekholuenetale, Temitope Cyrus Ekundayo, Iman El Sayed, Muhammed Elhadi, Waseem El-Huneidi, Sherif Elkannishy, Mohamed A Elmonem, Mohamed Hassan Elnaem, Christopher Imokhuede Esezobor, Derese Eshetu, Juan Espinosa-Montero, Adeniyi Francis Fagbamigbe, Maryam Farooqui, Alireza Feizkhah, Ginenus Fekadu, Nuno Ferreira, Florian Fischer, Federica Fogacci, Celia Fortuna Rodrigues, Marisa Freitas, Ami Fukunaga, Abdelrahman Gamil Gad, Abhay Motiramji Gaidhane, Abdurhappar Gaipov, Balasubramanian Ganesh, Miglas Welay Gebregergis, Kalab Yigermal Gete, Lobna Gharaibeh, Mohammadreza Ghasemi, Zainab Gholami, Ehsan Gholami, Alem Abera Girmay, Amit Goel, Mahaveer Golechha, Aman Goyal, Ashna Grover, Shi-Yang Guan, Rajat Das Gupta, Rajeev Gupta, Ashna Kumar Gupta, Sapna Gupta, Jose Guzman-Esquivel, Najah R Hadi, Arian Haghtalab, Hailey Hagins, Nadia M Hamdy, Mohammad Hamza, Qiuxia Han, Hamidreza Hasani, Mohammad Hashem Hashempur, Md Saquib Hasnain, Ibrahim Nagmeldin Hassan, Simon I Hay, Jiawei He, Golnaz Heidari, Yuta Hiraike, Praveen Hoogar, Alamgir Hossain, Mehdi Hosseinzade, Mihaela Hostiuc, Mengsi Hu, Hong-Han Huynh, Segun Emmanuel Ibitoye, Umar Idris Ibrahim, Irena M Ilic, Mohammad Tarique Imam, Lalu Muhammad Irham, Mustafa Alhaji Isa, Dr. Md. Shahinul Islam, Md Rabiul Islam, Md Fakrul Islam, Nahlal Elkudssiah Ismail, Hiroyasu Iso, Gaetano Isola, Masao Iwagami, Vennila Jaganathan, Ammar Abdulrahman Jairoun, Navid Jamali, Jazlan Jamaluddin, Rajiv Janardhanan, Shubha Jayaram, Mohammed Jamal, Seongsong Jeong, Vivekanand Jha, Nathan T Jibat, Jost B Jonas, Nitin Joseph, Akaninyene Paul Joseph, Charity Ehimwenma Joshua, Kripa Josten, Jacek Jerzy Jozwiak, Sang-Hyuk Jung, Zubair Kabir, Ali Kabir, Ashish Kumar Kakkar, Sanjay Kalra, Md Moustafa Kamal, Ashwin Kamath, Edmund Wedam Kanmiki, Kehinde Kazeem Kanmadi, Debasish Kar, Reema A Karasneh, Samad Karkhah, Mohd Adnan Kausar, Yabets Tesfaye Kebede, Abenezer Zenebe Kebede, Yousef Saleh Khader, Himanshu Khajuria, Anees Ahmed Khalil, Abdul Arif Khan, Mohammad Jobair Khan, Sumaiya Khan, Ajmal Khan, Iqra Hamid Khan, Sameer Uttamaro Khasbaga, Zenith Khashim, Moawiah Mohammad Khatatbeh, Feriha Fatima Khidri, Manoj Khokhar, Adnan Kisa, Mika Kivimäki, Abdul Basith KM, Nazarii Kobyljak, Michail Kokkorakis, Farzad Kompani, Tapos Kormoker, Oleksii Korzh, Karel Kostev, Sindhura Lakshmi Koulmane Laxminarayana,

Irene Akwo Kretchy, Kewal Krishan, Yuvaraj Krishnamoorthy, Barthelemy Kuate Defo, Mohammed Kuddus, Mukhtar Kulimbet, Jogender Kumar, G Anil Kumar, Tushar Kumar, Rakesh Kumar, Setor K Kunutsor, Maria Dyah Kurniasari, Ambily Kuttikkattu, John Paul Kuwornu, Ville Kytö, Chandrakant Lahariya, Iván Landires, Duc Tin Le, Minh Huu Nhat Le, Caterina Ledda, Hwamin Lee, Dawit Alemu Lemma, Andrew S Levey, Chengfeng Li, Jinbo Li, Lee-Ling Lim, Xuefeng Liu, Zhenyu Liu, jinshi Liu, Zhe Liu, Erand Llanaj, Giancarlo Lucchetti, Jay B Lusk, Angelina M Lutambi, Lei Lv, Raymond Saa-Eru Maalman, Sasikumar Mahalingam, Nozad Hussein Mahmood, Azeem Majeed, Omar M Makram, Tabarak Malik, Ahmad Azam Malik, Abdullah A Mamun, Ramon Martinez-Piedra, Winfried März, Sammer Mazouk, Stefano Masi, Soroush Masrouri, Mohsen Mazidi, Steven M McPhail, Jitendra Meena, Asim Mehmood, Sadrollah Mehrabi, Hadush Negash Meles, Tomislav Mestrovic, Chamila Dinushi Kukulege Mettananda, Tomasz Miazgowski, Keadnew Mulatu Mihretie, Muhammad Agus Mikrajab, Andreea Mirica, Erkin M Mirrakhimov, Vinaytosh Mishra, Amaresh Mishra, Prasanna Mithra, Nohu Saad Mohamed, Abdolreza Mohammadi, Shafiu Mohammed, Ali H Mokdad, Stefania Mondello, Mohammad Ali Moni, Negar Morovatdar, Amin Mousavi Khaneghah, Mohamed Awad Abdalaziz Mousnad, Godfrey Mudhune, Efran Murillo-Zamora, Christopher J L Murray, Mubarak Taiwo Mustapha, SeyedAli Nabipoorashrafi, Shankar Prasad Nagaraju, Hiten Naik, Tapas Sadasivan Nair, Shumaila Nargus, Abdallah Y Naser, Mohammad Naser, Mahmoud Nassar, Gopalakrishnan Natarajan, Zuhair S Natto, Javaid Nauman, Shalini Ganesh Nayak, Bruce Neal, Xurandra Irina Nego, Omid Nekouei, Hau Thi Hien Nguyen, Trang Nguyen, Nghia Phu Nguyen, Tu Anh Nguyen, Hien Thu Nguyen, Huong Lan Thi Nguyen, Thao Phuong Nguyen, Robina Khan Niazi, Luciano Nieddu, Shuhei Nomura, Mamoon Noreen, Jean Jacques Noubiap, Fred Nugen, Chijindu N Nwakanma, Felix Kwasi Nyande, Chimezie Igwegbe Nzopotam, Bogdan Oancea, Osaretin Christabel Okonji, Patrick Godwin Okwute, Andrew T Olagunju, Timothy Olusegun Olanrewaju, Abdullahi Olaleye Olawuyi, Abdulhakeem Abayomi Olorukooba, Alberto Ortiz, Alaa AM Osman, John W Ostrominski, Elham H Othman, Mayowa O Owolabi, Ifeoluwa Temitayo Oyeyemi, Alicia Padron-Monedero, Jagadish Rao Padubidri, Adrian Pana, Ke Pang, Anca Pantea Stoian, Ilias Papadimopoulos, Shahina Pardhan, Romil R Parikh, Maja Pasovic, Dimitrios Patoulas, Prince Peprah, Norberto Perico, Simone Perna, Kevan R Polkinghorne, Djordje S Popovic, Thantrira Pornaveetus, Akila Prashant, Jagadeesh Puvvula, Xiang Qi, Basuki Rachmat, Quinn Rafferty, Muhammad Aziz Rahman, Mosiur Rahman, Masoud Rahmati, Sunil Kumar Raina, Adarsh Raja, Prashant Rajput, Mahmoud Mohammed Ramadan, Sheena Ramazanu, Rishabh Kumar Rana, Asad Gul Rao, Ashkan Rasouli-Saravani, Devarajan Rathish, Santosh Kumar Rauniyar, Salman Rawaf, Lal Rawal, Murali Mohan Rama Krishna Reddy, Elrashdy Redwan, Giuseppe Remuzzi, Nazila Rezaei, Leonardo Roeveer, Peter Rohloff, Debby Syahrul Romadlon, Allen Guy Patrick Ross, Hanieh Rouzbahani, Aly M A Saad, Basema Ahmad Saddik, Umar Saeed, Mohd Saeed, Maryam Saeedi, Fatemeh Saheb Sharif-Askari, Amirhossein Sahebkar, Afeez Abolarinwa Salami, Mohamed A Saleh, Yoseph Leonardo Samodra, Vijaya Paul Samuel, Itamar S Santos, Aswini Saravanan, Saman Sargazi, Michele Sassano, Brijesh Sathian, Monika Sawhney, Maria Inês Schmidt, Art Schuermans, Hamidreza Seifmanesh, Siddharthan Selvaraj, Yashendra Sethi, Allen Seylani, Moyad Jamal Shahwan, Masood Ali Shaikh, Sunder Sham, Muhammad Aaqib Shamim, Xian Shao, Amin Sharifan, Bunty Sharma, Sourabh Sharma, Shamee Shastri, Wenming Shi, Md Monir Hossain Shimul, Aminu Shittu, Abdul-karim Olayinka Shitu, Sunil Shrestha, Aman Shrestha, Padam Prasad Simkhada, Jasvinder A Singh, Harmanjit Singh, Narinder Pal Singh, Surjit Singh, Suha Soni, Aayushi Sood, Soroush Sorane, Reed J D Sorensen, Sandra Spearman, Saraswathy Sreeram, Antonina V Starodubova, Leo Stockfelt, Hasnat Sujon, Oksana Sulaieva, Muritala Suleiman Odidi, Muhammad Suleman, Desy Sulistiyorini, Xiaodong Sun,

Johan Sundström, Dev Ram Sunuwar, Hani Susianti, Chandan Kumar Swain, Lukasz Szarpak, Sree Sudha T Y, Celine Tabche, Iman M Talaat, Seyed Saeed Tamehri Zadeh, Roberto C Tanchanco, Kaleab Tesfaye Tegegne, Abainash Tekola, Masayuki Teramoto, Wubshet H Tesfaye, Jay Tewari, Jansje Henny Vera Ticoalu, Krishna Tiwari, Sojit Tomo, Santo Imanuel Tonapa, Marcello Tonelli, Khaled Trabelsi, Thang Huu Tran, Quynh Thuy Huong Tran, Tam Quoc Minh Tran, Nguyen Tran Minh Duc, Domenico Trico, Zhouting Tuo, Sok Cin Tye, Himayat Ullah, Pascual R Valdez, Jef Van den Eynde, Joe Varghese, Priya Vart, Shoban Babu Varthya, Sampara Vasishta, Sharath Chaitanya Vipparthy, Yasir Waheed, Jingyu Wang, Wanzhou Wang, Zhihua Wang, Qingzhi Wang, Ziyue Wang, Yanzhong Wang, Ishanka Weerasekara, Jordan Weiss, Andrea Werdecker, Ronny Westerman, Nuwan Darshana Wickramasinghe, Angga Wilandika, Peter Willeit, Marcin W Wojewodzic, Yen Jun Wong, Shijie Wu, Qing Xia, Zhaomin Xie, Saba Yahoo (Syed), Galal Yahya, Kazumasa Yamagishi, Haibo Yang, Haiqiang Yao, Laiang Yao, Pengpeng Ye, Kuanysh A. Yergaliyev, Thomas Kidanemariam Yewodaiw, Malede Berihun Yismaw, Dong Keon Yon, Naohiro Yonemoto, Yong Yu, Emad Yuzbashian, Sojib Bin Zaman, Nelson Zamora, Mohammed Zawiah, Haijun Zhang, Danting Zhang, Beijian Zhang, Xuying Zhang, Zhiqiang Zhang, Yue Zhang, Hanqing Zhao, Abzal Zhumagaliuly, Magdalena Zielińska, Sa'ed H Zyoud, Theo Vos†, Jennifer Susan Lees†, Kanyin Liane Ong†, Josef Coresh†

*Lead authors. †Senior authors.

Affiliations

Please see appendix 2 (pp 4–19) for the affiliations for individual authors.

Contributors

Please see appendix 2 (pp 20–25) for more detailed information about individual author contributions to the research, divided into the following categories: providing data or critical feedback on data sources; developing methods or computational machinery; providing critical feedback on methods or results; drafting the manuscript or revising it critically for important intellectual content; and managing the estimation or publications process.

Declaration of interests

J Årnlöv reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Boehringer Ingelheim, and Novartis; and participation on a data safety monitoring board or advisory board from AstraZeneca, Boehringer Ingelheim, and Astella; outside the submitted work. D Abramov reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Bayer and AstraZeneca; participation on a data safety monitoring board or advisory board from BridgeBio; and receipt of equipment, materials, drugs, medical writing, gifts, or other services from Bayer; outside the submitted work. O C Baltatu reports support for the present manuscript from the National Council for Scientific and Technological Development Fellowship (CNPq, 304224/2022-7), Anima Institute (AI) Research Professor Fellowship, Alfaist University; leadership or fiduciary roles in other board, society, committee or advocacy groups, paid or unpaid from VividiWise Analytics as Managing Partner and São José dos Campos Tech Park–CITE as Biotech Advisory Board Member, outside the submitted work. A K Bello reports grants or contracts from the Canadian Institute of Health Research, Heart and Stroke Foundation of Canada, Amgen Incorporated, Canada; consulting fees from Amgen, AstraZeneca, Bayer, Glaxosmith, Otsuka, and Novo Nordisk; leadership or fiduciary roles in other board, society, committee or advocacy groups, paid or unpaid as co-chair of the Global Kidney Health Atlas ISN; outside the submitted work. A S Bhagavathula reports support for attending meetings or travel, or both, to attend conferences from the North Dakota State University, American College of Epidemiology, and University of Virginia; leadership or fiduciary roles in other board, society, committee or advocacy groups, paid or unpaid as a member of the Board of Directors, American College of Epidemiology and GBD Lead Collaborator; outside the submitted work. S Bhaskar reports grants or contracts from the Japan Society for the Promotion of Science (JSPS), Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT), Grant-in-Aid for Scientific Research (KAKENHI; Grant ID 23KF0126), JSPS, and the

Australian Academy of Science, JSPS International Fellowship (Grant ID P23712); leadership or fiduciary roles in other board, society, committee or advocacy groups, paid or unpaid as District Chair, Diversity, Equity, Inclusion & Belonging of Rotary District 9675 (Sydney, Australia), as Chair, Founding Member and Manager of the Global Health & Migration Hub Community, Global Health Hub Germany (Berlin, Germany), as Editorial Board Member of *PLoS One*, *BMC Neurology*, *Frontiers in Neurology*, *Frontiers in Stroke*, *Frontiers in Public Health*, *Journal of Aging Research*, *Neurology International*, *Diagnostics*, and *BMC Medical Research Methodology*, as a member of the College of Reviewers, Canadian Institutes of Health Research (CIHR), Government of Canada, as the Director of Research of the World Headache Society (Bengaluru, India), as Expert Adviser/Reviewer of Cariplo Foundation (Milan, Italy), as Visiting Director of National Cerebral and Cardiovascular Center, Department of Neurology, Division of Cerebrovascular Medicine and Neurology, Suita (Osaka, Japan), as Member, Scientific Review Committee of Cardiff University Biobank (Cardiff, UK), as Chair of Rotary Reconciliation Action Plan, and Healthcare and Medical Adviser at Japan Connect (Osaka, Japan); outside the submitted work. M Carvalho reports support from Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES) under the scope of the project UIDP/50006/2020 (<https://doi.org/10.54499/UIDP/50006/2020>) LAQV/REQUIMTE, University of Porto, Porto, Portugal, outside the submitted work. A L Catapano reports grants or contracts from Chiesi, Amarin, Ultragenyx; consulting fees from Amarin, Amgen, AstraZeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Medscape, Menarini, MSD, Novartis, Novo Nordisk, Regeneron, Sanofi, Ultragenyx, and Viatrix; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Amarin, Amgen, AstraZeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Medscape, Menarini, MSD, Novartis, Novo Nordisk, Regeneron, Sanofi, Ultragenyx, and Viatrix; participation on a data safety monitoring board or advisory board with Amarin, Amgen, AstraZeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Medscape, Menarini, MSD, Novartis, Novo Nordisk, Regeneron, Sanofi, Ultragenyx, and Viatrix; outside the submitted work. J Coresh reports support for the present manuscript from the US National Institutes of Health and US National Kidney Foundation; grants or contracts from the US National Institutes of Health and US National Kidney Foundation; royalties or licenses from Health.IO; participation on a data safety monitoring board or advisory board from Health.IO; and stock or stock options from Health.IO; outside the submitted work. I M Ilic reports support for the present manuscript from the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (number 451-03-137/2025-03/200110). N E Ismail reports leadership or fiduciary roles in other board, society, committee or advocacy groups, unpaid as The Bursar and Council Member, Malaysian Academy of Pharmacy, Malaysia and as Committee Member, Malaysian Pharmacists Society Education Chapter Committee; outside the submitted work. V Jha reports grants or contracts from Variant Bio (paid to the George Institute); and consulting fees from Bayer, AstraZeneca, Boehringer Ingelheim, Baxter, Vera, Visterra, Otsuka, Novartis, Tim-berlyne, Biogen, Chinook, and Alpine (paid to the George Institute); outside the submitted work. J J Jozwiak reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis, Adamed, Amgen, Boehringer Ingelheim, Servier, and Novo Nordisk; outside the submitted work. M Kivimäki reports grants or contracts from the Wellcome Trust (221854/Z/20/Z), Medical Research Council (MR/Y014154/1), and Research Council of Finland (350426); outside the submitted work. K Krishan acknowledges non-financial support from the UGC Centre of Advanced Study, CAS II, awarded to the Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. J S Lees reports consulting fees from Boehringer Ingelheim; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca; outside the submitted work. A S Levey reports grants or contracts from the US National Institutes of Health and National Kidney Foundation; and royalties or licences from UpToDate; outside the submitted work. P B Mark reports grants or contracts from AstraZeneca, and Boehringer Ingelheim; consulting fees

from AstraZeneca, Boehringer Ingelheim, Pharmacosmos, and Vifor; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Boehringer Ingelheim, Pharmacosmos, Bayer, and Vifor; and participation on a data safety monitoring board or advisory board from Vertex and Novartis; outside the submitted work. S Masi reports grants or contracts from Servier; consulting fees from Servier; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Servier; support for attending meetings or travel, or both, from Servier; participation on a data safety monitoring board or advisory board from Servier; and leadership or fiduciary roles in other board, society, committee or advocacy groups, paid or unpaid from the Italian Society of Internal Medicine; outside the submitted work. S A Nabipoorashrafi reports grants or contracts from GE Healthcare and North American Society for Cardiovascular Imaging (NASCI); outside the submitted work. S Nomura reports support for the present manuscript from the Ministry of Education, Culture, Sports, Science and Technology of Japan (grant 24H00663) and from Precursory Research for Embryonic Science and Technology from the Japan Science and Technology Agency (grant JPMJPR22R8). B Oancea reports support for the present manuscript from the Ministry of Research, Innovation and Digitalization through the Core Program of the National Research, Development and Innovation Plan 2022–27, project number PN 23-02-0101-Contract No. 7N/2023; PNRR/2022/C9/MCID/18 project 760096. A Ortiz reports grants or contracts as Director of the Catedra AstraZeneca-Universidad Autonoma de Madrid of chronic kidney disease and electrolytes (Grants to Universidad Autonoma de Madrid), and grants from Sanofi (to their institution: The Fundación Jiménez Díaz Health Research Institute [IIS-FJD, UAM]); consulting fees from Astellas, AstraZeneca, Bioparto, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Lilly, Chiesi, Otsuka, Novo Nordisk, Sysmex; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Astellas, AstraZeneca, Bioparto, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Sobi, Menarini, Lilly, Chiesi, Otsuka, Novo Nordisk, Sysmex, Vifor Fresenius Medical Care Renal Pharma, and Spafarma; support for attending meetings or travel, or both, from Astellas, AstraZeneca, Fresenius Medical Care, Boehringer Ingelheim, Bayer, Sanofi-Genzyme, Chiesi, Sobi, and Bayer; participation on a data safety monitoring board or advisory board from Astellas, AstraZeneca, Boehringer Ingelheim, Fresenius Medical Care, Bayer, Sanofi-Genzyme, Chiesi, Otsuka, Novo Nordisk, and Sysmex; leadership or fiduciary roles in other board, society, committee or advocacy groups, unpaid with Council ERA and the Sociedad Madrileña de Nefrología (SOMANE); outside the submitted work. Y L Samodra reports grants or contracts from the National Science and Technology Council (Taiwan) – Institute of Epidemiology and Preventive Medicine National Taiwan University, Taiwan; leadership or fiduciary roles in other board, society, committee or advocacy groups, paid or unpaid from Benang Merah Research Center (co-founder), Indonesia; and other financial or non-financial interests as scholarship advisor from Jago Beasiswa (<https://idebeasiswa.com>); outside the submitted work. J A Singh reports consulting fees from ROMTech, Atheneum, Clearview Healthcare Partners, American College of Rheumatology, Yale, Hulo, Horizon Pharmaceuticals, DINO-RA, ANI/Exeltis, USA Inc, Frictionless Solutions, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc, Adept Field Solutions, Clinical Care Options, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point communications; and the National Institutes of Health; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Simply Speaking; support for attending meetings or travel, or both, from OMERACT as a past steering committee member; participation on a data safety monitoring board or advisory board from FDA Arthritis Advisory Committee; leadership or fiduciary roles in other board, society, committee or advocacy groups, paid or unpaid as a past steering committee member of the OMERACT, an international organisation that develops measures for clinical trials and receives arm's length funding from 12 pharmaceutical companies; stock or stock options in Atai Life Sciences, Kintara Therapeutics, Intelligent Biosolutions, Acumen Pharmaceutical, TPT Global Tech, Vaxart Pharmaceuticals, Atyu

Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics, Seres Therapeutics, Tonix Pharmaceuticals Holding, Aebona Pharmaceuticals, and Charlotte's Web Holdings, and previously owned stock options in Amarin, Viking, and Moderna pharmaceuticals; outside the submitted work. J Sundström reports direct or indirect stock ownership in companies (Anagram kommunikation, Sence Research, Symptoms Europe, MinForskning) providing services to companies and authorities in the health sector, including Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Göteborg University, Itrim, Ipsen, Janssen, Karolinska Institutet, LIF, Linköping University, Novo Nordisk, Parexel, Pfizer, Region Stockholm, Region Uppsala, Sanofi, STRAMA, Takeda, TLV (The Dental and Pharmaceutical Benefits Agency; Tandvårds- och läkemedelsförmånsverket; affiliated with Uppsala University), Uppsala University, Vifor Pharma, and WeMind; outside the submitted work. R C Tanchanco reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca; support for attending meetings or travel, or both, from AstraZeneca, and Boehringer Ingelheim; leadership or fiduciary roles in other board, society, committee or advocacy groups, paid or unpaid on the Council of Past Presidents, Philippine Society of Nephrology Oceania South East Asia Regional Board member, International Society of Nephrology; outside the submitted work. J H V Ticoalu reports leadership or fiduciary roles in other board, society, committee or advocacy groups, paid or unpaid from Benang Merah Research Center, Indonesia (as co-founder); outside the submitted work. D Trico reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Eli Lilly, and Novo Nordisk; support for attending meetings or travel, or both, from AstraZeneca; participation on a data safety monitoring board or advisory board from Amarin, Boehringer Ingelheim, and Novo Nordisk; leadership or fiduciary roles in other board, society, committee or advocacy groups, paid or unpaid from the EASD Early Career Academy and EASD Committee on Clinical Affairs; receipt of equipment, materials, drugs, medical writing, gifts, or other services from Abbott and PharmaNutra; outside the submitted work. P Willeit reports consulting fees from Novartis Pharmaceuticals; outside the submitted work. M Zielińska reports other financial or non-financial interests as an Alexion AstraZeneca Rare Disease employee; outside the submitted work. All other authors declare no competing interests.

Data sharing

Citations for the data used in these analyses are provided in appendix 1 (table S19), with further information available on the Global Health Data Exchange website: <https://ghdx.healthdata.org>. The statistical code used for data processing and analysis is available upon request via email to the corresponding author.

Acknowledgments

This study is funded by the Gates Foundation. The CKD Prognosis Consortium (CKD-PC) Data Coordinating Center is funded in part by a programme grant from the US National Kidney Foundation and the US National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100446). JSL is personally funded by a Wellcome Trust Early Career Award (301005/Z/23/Z).

Editorial note: The Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.

References

- 1 GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2020; **395**: 709–33.
- 2 Stevens PE, Ahmed SB, Carrero JJ, et al, and the Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int* 2024; **105**: S117–314.
- 3 GBD 2023 Kidney Failure with Replacement Therapy Collaborators. Global, regional, and national prevalence of kidney failure with replacement therapy and associated aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. *Lancet Glob Health* 2025; **13**: e1378–95.

- 4 Grams ME, Coresh J, Matsushita K, et al, and the Writing Group for the CKD Prognosis Consortium. Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis. *JAMA* 2023; **330**: 1266–77.
- 5 Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020; **584**: 430–36.
- 6 Duff R, Awofala O, Arshad MT, et al. Global health inequalities of chronic kidney disease: a meta-analysis. *Nephrol Dial Transplant* 2024; **39**: 1692–709.
- 7 GBD 2021 Adolescent BMI Collaborators. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. *Lancet* 2025; **405**: 785–812.
- 8 GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2023; **402**: 203–34.
- 9 Chesnaye NC, Ortiz A, Zoccali C, Stel VS, Jager KJ. The impact of population ageing on the burden of chronic kidney disease. *Nat Rev Nephrol* 2024; **20**: 569–85.
- 10 Gbadegesin RA, Ulasi I, Ajayi S, et al, and the H3Africa Kidney Disease Research Network. *APOL1* bi- and monoallelic variants and chronic kidney disease in West Africans. *N Engl J Med* 2025; **392**: 228–38.
- 11 Anand S, Montez-Rath ME, Adasooriya D, et al. Prospective biopsy-based study of CKD of unknown etiology in Sri Lanka. *Clin J Am Soc Nephrol* 2019; **14**: 224–32.
- 12 GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; **403**: 2100–32.
- 13 Stevens GA, Alkema L, Black RE, et al, and The GATHER Working Group. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. *Lancet* 2016; **388**: e19–23.
- 14 Johnson SC, Cunningham M, Dippenaar IN, et al, and the GBD Cause of Death Collaborators. Public health utility of cause of death data: applying empirical algorithms to improve data quality. *BMC Med Inform Decis Mak* 2021; **21**: 175.
- 15 Bikbov B, Perico N, Remuzzi G, Group GBDGDE, and the GBD Genitourinary Diseases Expert Group. A comparison of metrics and performance characteristics of different search strategies for article retrieval for a systematic review of the global epidemiology of kidney and urinary diseases. *BMC Med Res Methodol* 2018; **18**: 110.
- 16 Levey AS, Stevens LA, Schmid CH, et al, and the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009; **150**: 604–12.
- 17 Inker LA, Eneanya ND, Coresh J, et al, and the Chronic Kidney Disease Epidemiology Collaboration. New creatinine- and cystatin C-based equations to estimate GFR without race. *N Engl J Med* 2021; **385**: 1737–49.
- 18 Zheng P, Barber R, Sorensen RJD, et al. Trimmed constrained mixed effects models: formulations and algorithms. *J Comput Graph Stat* 2021; **30**: 544–56.
- 19 GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; **403**: 2133–61.
- 20 Burkart KG, Brauer M, Aravkin AY, et al. Estimating the cause-specific relative risks of non-optimal temperature on daily mortality: a two-part modelling approach applied to the Global Burden of Disease Study. *Lancet* 2021; **398**: 685–97.
- 21 Zheng P, Afshin A, Biryukov S, et al. The Burden of Proof studies: assessing the evidence of risk. *Nat Med* 2022; **28**: 2038–44.
- 22 GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; **403**: 2162–203.
- 23 Matsushita K, van der Velde M, Astor BC, et al, and the Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010; **375**: 2073–81.
- 24 GBD 2021 Demographics Collaborators. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; **403**: 1989–2056.
- 25 WHO. Reducing the burden of noncommunicable diseases through promotion of kidney health and strengthening prevention and control of kidney disease. Feb 10, 2025. [https://apps.who.int/gb/ebwha/pdf_files/EB156/B156_\(20\)-en.pdf](https://apps.who.int/gb/ebwha/pdf_files/EB156/B156_(20)-en.pdf) (accessed Oct 23, 2025).
- 26 Shin JI, Xu Y, Chang AR, et al. Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S. health systems. *J Am Coll Cardiol* 2024; **84**: 683–93.
- 27 Zhang J, Wang B, Ye B, Zhu B, Liu Y. Association between heatwave exposure and rapid kidney function decline: a longitudinal cohort study from CHARLS. *BMC Public Health* 2025; **25**: 1596.
- 28 Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic utility of exome sequencing for kidney disease. *N Engl J Med* 2019; **380**: 142–51.
- 29 Baigent C, Emberson J, Haynes R, et al, and the Nuffield Department of Population Health Renal Studies Group, and the SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. *Lancet* 2022; **400**: 1788–801.
- 30 Bakris GL, Agarwal R, Anker SD, et al, and the FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med* 2020; **383**: 2219–29.
- 31 Perkovic V, Tuttle KR, Rossing P, et al, and the FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N Engl J Med* 2024; **391**: 109–21.
- 32 GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet* 2024; **403**: 2100–32.
- 33 Shin JI, Chang AR, Grams ME, et al, and the CKD Prognosis Consortium. Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium. *Hypertension* 2021; **78**: 1042–52.
- 34 Hull SA, Nitsch D, Caplin B, Griffith K, Wheeler DC. The National CKD Audit: a primary care condition that deserves more attention. *Br J Gen Pract* 2018; **68**: 356–57.
- 35 Bello A, Okpechi IG, Levin A, et al. ISN–Global Kidney Health Atlas: a report by the International Society of Nephrology: an assessment of global kidney health care status focussing on capacity, availability, accessibility, affordability and outcomes of kidney disease. 2023. https://www.theisn.org/wp-content/uploads/media/ISN%20Atlas_2023%20Digital_REV_2023_10_03.pdf (accessed Oct 7, 2025).